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ABSTRACT 
Norepinephrine is a catecholamine neurotransmitter that signals through the 
adrenergic receptors (ARs), α1, α2, and β, each with three subtypes. There is little research 
on the function of α1AR subtypes, α1A- and α1BARs, in the brain. By using α1AR agonists, 
antagonists, and transgenic activation there appears to be a role for the subtypes in 
learning, memory, mood, adult neurogenesis, and cancer.  
α1AAR activation enhances learning and memory in the adult mouse. In the current 
study, we used α1A- or α1BAR knockout mice (α1AAR or α1BAR-KO mice) and behavioral 
testing to examine learning, memory, depression, and anxiety. We found that KO of each 
α1AR subtype impairs novel object recognition, but not spatial memory. KO of either 
subtype did not reliably affect anxiety behavior. α1BAR-KO mice had a significantly lower 
depression level than wild type mice.  
Activation of the α1AAR subtype increases proliferation of neural progenitor cells in 
the adult mouse dentate gyrus and in vitro work suggested a role in the differentiation 
stage. We used the α1AAR agonist, cirazoline, BrdU incorporation, and 
immunohistochemistry to determine whether activation of the α1AAR would direct cell fate 
toward an astrocytic phenotype in the adult mouse dentate gyrus. Cirazoline did not change 
the number or percent of new cells differentiating into neurons or astrocytes. The number 
of immature neurons was also not different.
xviii 
 
The α1BAR was proposed as a proto-oncogene based on in vitro and tumorigenesis 
studies. An age-related neurodegenerative disorder occurs when a constitutively active 
mutant form of the receptor is overexpressed in mice (CAM-α1BAR mice). We tracked CAM-
α1A- and CAM-α1BAR mouse lifespan, and performed gross pathology and histology to 
determine cancer occurrence. CAM-α1AAR mice had an increased lifespan and decreased 
cancer incidence. CAM-α1BAR mice had decreased lifespan but no change in cancer 
incidence.  
Further research should pursue the mechanism of the α1AR subtypes’ role in mood 
and cancer incidence. The use of α1AAR activation and of α1BAR blocking should be 
examined in a mouse model of depression to determine the benefit as treatments. 
Heterodimerization of the receptors is also a potential mechanism. 
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CHAPTER 1 
INTRODUCTION 
The Noradrenergic System 
Epinephrine, commonly known as adrenaline, and norepinephrine (noradrenaline) 
are signaling molecules synthesized and used in both the peripheral and central nervous 
systems. In the peripheral nervous system, synthesis occurs in the adrenal medulla where 
they are released into the bloodstream and act as hormones (von Euler, 1951; Outschoorn, 
1952). In the central nervous system, the hindbrain houses the cell bodies that synthesize 
both molecules.  
Adrenergic and noradrenergic neurons are located in the medulla and pons (Grzanna 
and Fritschy, 1991). The medullary nucleus includes both adrenergic and noradrenergic cell 
bodies that project to the spinal cord where they synapse onto preganglionic acetylcholine 
cells to regulate autonomic function (Swanson and Hartman, 1975). The medullary nucleus 
also has fibers that project to the limbic system. The locus coeruleus nuclei are located near 
the fourth ventricle in the dorsal pons and contain up to 50,000 neurons, including both left 
and right nuclei, in the human brain (Ohm et al., 1997).  
Norepinephrine derives from the amino acid L-tyrosine in three steps requiring the 
enzymes tyrosine hydroxylase, DOPA decarboxylase, and dopamine β-hydroxylase (Figure 
1). Intermediates in the process are L-DOPA and dopamine. Immunolabeling for dopamine  
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Figure 1. Synthesis of norepinephrine and epinephrine. 
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β-hydroxylase is one way to track noradrenergic projections in the brain. Almost every 
region contains some level of noradrenergic input based on dopamine β-hydroxylase 
studies (Swanson and Hartman, 1975). There are only a few areas of the brain that do not 
contain dopamine β-hydroxylase. These include the caudate-putamen, nucleus accumbens, 
globus pallidus, subthalamic nucleus, and substantia nigra (pars reticulata and compacta). 
Noradrenergic projections have also been characterized using autoradiology and axonal 
transport studies (Segal et al., 1973; Jones et al., 1977; Jones and Moore, 1977; Loughlin et 
al., 1986). These studies showed that specific areas of the locus coeruleus project to 
different brain regions. The rostral and medial portion of the locus coeruleus is comprised 
entirely of noradrenergic cell bodies, which project to the hippocampus, hypothalamus, and 
virtually all areas of the cortex (Loughlin et al., 1986) (Figure 2). The ventral area of the 
locus coeruleus contains both noradrenergic and adrenergic cells that project descending 
fibers to the spinal cord and cerebellum. Noradrenergic terminations in the spinal cord are 
important for sympathetic nervous system functions such as heart rate. Noradrenergic cells 
release norepinephrine, which bind to receptors for their effects. 
Characterization of the Adrenergic Receptors 
Pharmacological 
The adrenergic receptors were characterized using both pharmacological and 
genetic means, as better techniques became available. Prior to the advent of the term 
“receptor”, substances were applied to isolated tissues and the effects observed to 
characterize their function. Using this technique, Raymond Ahlquist showed that 
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Figure 2. Locus coeruleus subregions and projections. “A schematic diagram of a sagittal view of 
locus coeruleus indicating proposed subdivisions, with the predominant cell type and efferents for 
each. Dorsal is up and anterior is to the right. Cb, cerebellum; cx, cortex; hpc, hippocampus; hyp, 
hypothalamus; sp cord, spinal cord.” From Loughlin et al., 1986.   
 
isoproterenol relaxed smooth muscle, norepinephrine contracted it, and epinephrine could 
do both (Ahlquist, 1948). In 1967, two types of receptors were proposed to bind the 
substances Ahlquist had been using in order to enact relaxation and contraction of smooth 
muscle (Furchgott, 1967). The two receptor types were characterized by rank order of 
agonist potencies.  
For αARs, the potencies were: epinephrine = norepinephrine > isoproterenol. In 
contrast, βARs had an almost opposite profile: isoproterenol > epinephrine > 
norepinephrine (Lands et al., 1967). Radioligand binding studies using tritiated antagonists 
later confirmed the existence of at least two subtypes: α and βARs. In the early 1970s, the 
discovery of the receptors’ downstream effects was only beginning.  
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Early work with hormone receptors showed there was an intermediate step 
between ligand binding and the downstream effect of adenylyl cyclase activation. Martin 
Rodbell showed this was due to guanine nucleotides (Pohl et al., 1971). Previously, 
researchers had been using preparations that were not as purified as they thought. They 
had inadvertently been adding nucleotides that masked the guanine-dependence of 
downstream effects. The first purified preparation of what came to be known as G-proteins 
was completed by Alfred G. Gilman’s lab in 1976 (Northup et al., 1980; Maguire et al., 1976; 
Gilman, 1984). By this time, researchers knew the adrenergic receptors were coupled to G-
proteins but they did not know how many subtypes there were.   
In the late 1980s, the α1A- and α1BAR subtypes were proposed based on tritiated 
antagonist radioligand binding studies (Morrow and Creese, 1986; Minneman et al., 1988). 
Classification of the adrenergic receptors at this time only included two major families: α- 
and βARs. α1ARs were further classified into the α1- and α2AR subtypes, with the α1AR being 
postsynaptic and the α2AR presynaptic (Figure 3A). David Bylund proposed, based on the 
pharmacological differences, differential coupling to G-proteins, and molecular cloning of 
the α2AR subtypes, that the α1- and α2ARs were as distinct as each compared with βARs 
(Bylund, 1988). Thus, he proposed the classification should be α1-,α2-, and βARs (Figure 3B). 
After addition of these subtypes, Bylund’s classification was officially adopted and modified 
as other receptor subtypes were discovered (Bylund et al., 1994; Hieble et al., 1995, Figure 
3C). 
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Figure 3. Classification of adrenergic receptors. A) traditional, B) proposed, and C) final 
classifications. Adapted from (Bylund, 1988; Bylund et al., 1994; Hieble et al., 1995). 
 
Genetic 
The advent of molecular cloning spurred a flurry of research to clone and confirm 
each adrenergic receptor subtype between 1986 and 1994. The α1A- and α1BAR were the 
first of the α1AR subtypes to be cloned (Cottecchia et al., 1988; Schwinn et al., 1991). The 
only α1AR subtype determined first by cloning rather than pharmacologically was the α1DAR 
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(Perez et al., 1991). Soon after, the α1CAR was found to be a variant of the α1AAR (Perez et 
al., 1994). Thus, the final classification for the α1ARs is α1A, α1B, and α1D (Figure 3C). Another 
benefit of cloning the receptors’ amino acid sequences was the ability to model the 
structure of the receptors.  
α1 Adrenergic Receptor Structure and Signaling  
Structure 
The sequences determined by cloning were used to create potential structures of 
the receptors. The models confirmed that the adrenergic receptors were part of the GPCR 
family. GPCRs are a type of metabotropic receptor. GPCRs mediate their effects through 
conformational changes during ligand binding, which activates proteins within the cell. The 
n-terminus of GPCRs is located on the extracellular side of the membrane and the c-
terminus on the intracellular side. All GPCRs have seven transmembrane helix domains and 
it is to the helices the ligand binds.  
In the late 1980s, Robert Lefkowitz and Brian Kobilka isolated the β2AR and deduced 
its possible structure from the amino acid sequence (Dixon et al., 1986). Kobilka’s group 
confirmed the structure of the β2AR bound to its G-protein using x-ray crystallography in 
2007 (Cherezov et al., 2007). Later, Kobilka’s group crystallized the β2AR again, but bound to 
both a ligand and the G-protein subtype, Gs (Rasmussen et al., 2011). Because both the 
amino acid sequence and structure of the β2AR is known, it is possible to model the 
potential structures of the other AR subtypes.  
Pairwise sequence alignment of the amino acid sequences of the β2- and α1AAR, 
shows there are 120 identical, 86 conserved, and 30 semi-conserved residues (Collette, 
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2010). Computer modeling allows these domains to be placed on the β2-AR structure to 
visualize where the differences are located (Figure 4A). Using the amino acid sequences and 
theoretical binding pockets, site-directed mutagenesis was used to determine the residues 
required for endogenous ligand binding (Strader et al., 1987). Norepinephrine, the common 
endogenous ligand in the brain, has three functional groups that participate in binding. 
These include the amine and alcohol groups, and the aromatic ring (with meta- and para-
hydroxyl groups, Figure 4B, Easson and Stedman, 1933). For the α1AAR, this includes 
residues on the third, fourth, and fifth transmembrane helices. The α1BAR ligand-binding 
pocket does not include a residue on the fourth helix but does on the sixth. The residues for 
binding are the same for both subtypes on the amine and meta-hydroxyl groups. They differ 
by only four residue positions on the para-hydroxyl group. The largest differences are in the 
residues that bind to the catechol ring of the endogenous ligands.  
Activation 
All GPCRs have constitutive activity in the absence of an agonist. They spontaneously 
isomerize between the R (inactive) and R* (activate) states. Agonists bind with a higher 
affinity to the R* state and, when bound, stabilize the R* state. This is known as the ternary 
model of agonist binding. The extended ternary model states there is more than one active 
state, such as R1* and R2*, which can activate different G-proteins (Roberts and 
Waelbroeck, 2004). The idea that one receptor in unique states of activation can affect 
different G-proteins is called agonist trafficking. An example would be a ligand that binds to 
the α1BAR as a full agonist and to the α1AAR as a partial agonist. The extended ternary model 
theorizes activation of different G-proteins and thus different downstream effects. One 
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Figure 4. Receptor conservation and norepinephrine structure. A) β2AR model with residues 
identical (red), conserved substitutions (orange), semi-conserved substitutions (yellow), and 
non-conserved residues (green), in the α1AAR (Collette, 2010), B) Norepinephrine structure 
with labeled functional groups (Acdx, 2009).  
 
effect may be to internalize the receptor while the other would activate the standard Gq 
pathway (Finch et al., 2006). Adrenergic receptor signaling depends on G-protein activation. 
Signaling 
There are many different types of G proteins. The most common are Gs (stimulates 
adenylyl cyclase), Gi (inhibits adenylyl cyclase), and Gq (mediates another pathway). Each G-
protein is bound to the intracellular side of a receptor and consists of three subunits α, β, 
and γ. G-proteins are associated with guanosine di- and tri-phosphates (GDP and GTP), 
which provide energy for subunit activation. When a ligand binds the receptor, the 
transmembrane helices change conformation which exposes the phosphorylation area of 
the G-protein (Farrens et al., 1996). When phosphorylated, the protein is active and the α 
subunit, Gαq, dissociates from the β and γ subunits, Gβγ, and slips along the membrane. 
The effects of the Gα subunit depend on the type of G-protein bound to the receptor.  
10 
 
 
Figure 5. Signaling pathway of α1ARs. The α1ARs signal through the α subunit of the Gq protein. 
The downstream effects including increasing intracellular calcium and phosphorylation of 
proteins. (Figure created by Collette, 2015.) 
 
The α1ARs are coupled to Gαq, which activates a specific downstream cascade 
within the cell (García-Sáinz et al., 2000, Figure 5). The α designates the subunit mediating 
the main effect of G-protein activation. In some cases, the Gβγ subunits also activate 
downstream effectors. When a ligand binds to the α1ARs, the Gαq moves along the 
membrane to a phospholipase C (PLC) protein. Gαq activates PLC, which cleaves 
phosphotidylinositol 4,5-bisphosphate (PIP2) into diacylglycerol (DAG) and inositol 
trisphosphate (IP3). DAG stays in the membrane and activates protein kinase C (PKC), which 
then phosphorylates other proteins. IP3 leaves the membrane and binds to IP3 receptors on 
11 
 
the endoplasmic reticulum. This releases free calcium ions into the cytosol, which mediate 
many downstream effects. An important part of GPCR signaling is signal amplification.  
Signal Amplification 
The downstream effect of activating receptors must be amplified to cause 
appreciable changes in cell function. Thousands of ligand molecules are released from the 
pre-synaptic terminal into the synapse where they bind to receptors on the post-synaptic 
cell. This is the first step of signal amplification. In the second step, one G-protein activates 
many of its direct downstream targets. In the case of α1ARs, the Gαq subunit can activate 
many PLC molecules that, in turn, cleave more than one PIP2 molecule. Thus, the signal is 
amplified at each step in the cascade.  
Deactivation 
Deactivation of the α1ARs includes 1) desensitization, 2) sequestration and 
internalization, and 3) downregulation (Finch et al., 2006). Desensitization is the quickest 
method of deactivation, taking seconds to minutes to occur, and involves uncoupling of the 
receptor from the G-protein. The α1BAR undergoes desensitization through phosphorylation 
by G-protein receptor kinases (GRKs) and PKC (Diviani et al., 1996). Once phosphorylated, β 
arrestin uncouples the receptor from the G-protein. α1BARs are constitutively internalized 
after ligand binding (Stanasila et al., 2008; Reviewed in Toews et al., 2003).  
After uncoupling, β arrestin sequesters the receptor by targeting it to clathrin 
adaptor complexes, such as AP2 (Stanasila et al., 2008). The receptor is internalized via 
endocytosis in clathrin-coated pits, taking minutes to hours. α1AARs are rarely internalized 
after ligand binding. When they are internalized, the process is slower than with α1BARs 
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(Chalothorn et al., 2002; Vázquez-Prado et al., 2000). The mechanism of α1AAR 
internalization is still elusive. It appears that GRKs and PKC can phosphorylate α1AARs prior 
to internalization but while PKC is sufficient for this, it is not necessary (Price et al., 2002). 
Furthermore, the carboxy tail of the α1BAR is the site of phosphorylation during 
internalization but PKC and GRK phosphorylation of α1AARs does not require the carboxy 
tail.  
Downregulation is the third mechanism of deactivation and is due to a decrease in 
the number of surface receptors. Downregulation can occur through internalization, 
increased degradation via the endosomal system, or reduced transcription of mRNA 
(Lefkowitz, 1998).  
The mechanisms of α1AR deactivation were studied in vitro, usually in cells 
transfected with the receptor in question (Stanasila et al., 2008). The process could be 
different in endogenous tissues and be tissue-dependent. The α1AR subtypes are expressed 
at different levels in tissues throughout the body.   
α1 Adrenergic Receptor Localization in the Brain 
Regional Expression 
Expression of the α1AR subtypes in the brain differs in distribution and expression 
level. Early work using tritiated antagonists showed α1AARs bind highly in the hippocampus 
and α1BAR mainly in the thalamus. Both subtypes were found in the cortex (Wilson and 
Minneman, 1989).   
Using in situ hybridization with a rat probe, α1AAR mRNA is expressed highly in the 
olfactory bulb, cortex, hypothalamus, and regions of the hindbrain (Domyancic and Morilak, 
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1997). The expression was moderate in the hippocampus but high in the granule cell layer 
of the dentate gyrus. The Allen Institute for Brain Science, also using in situ hybridization, 
showed α1AAR RNA in the cortex and olfactory bulb but little to none in the hippocampus 
(Allen Institute for Brain Science, 2014). This is in contrast to earlier comparative studies. 
The Allen Institute for Brain Science has not yet published data for the α1BAR subtype. 
However, another in situ experiment showed high expression in the cortex, reticular 
thalamic nucleus, and hypothalamus (Zuscik et al., 2000). The α1DAR is highly expressed in 
many regions of the brain, particularly the CA1 region of the hippocampus (Day et al., 1997; 
McCune et al., 1993; Pieribone et al., 1994). Using in situ hybridization, the Allen Brain 
Institute showed α1DAR expression high in the olfactory bulb, cerebellum, and mouse 
hippocampus (Allen Institute for Brain Science, 2014). In situ hybridization only shows that 
the gene is present in the cells and RNA expression is not well correlated with protein 
expression.  
Autoradiographic studies better imply protein expression because the radioligands 
must bind to the receptors. Autoradiography shows very high expression of α1ARs in human 
and primate hippocampus, especially the DG and CA3 regions, compared with rat brain 
(Palacios et al., 1987). The density of α1ARs in neocortex and thalamus are similar in rat, 
guinea pig, human, and non-human primate. These findings were comparable to other 
autoradiographic studies (Jones et al., 1985). The α1AAR mRNA is expressed in the dentate 
gyrus granule cell layer of the human hippocampus (Szot et al., 2005). Autoradiography is 
not helpful in α1DAR protein expression because of the receptors’ intracellular localization. 
In situ hybridization shows expression of α1DAR mRNA in the CA1, CA2, and CA3 regions. 
14 
 
α1BAR is not expressed in the human hippocampus. Currently, the most accurate way to 
determine localization is to use a promoter-based expression approach in transgenic mice.  
Mice with enhanced green fluorescent protein (EGFP) expressed under a large 
portion of the α1AAR endogenous promoter were created to localize protein expression in 
the brain (Papay et al., 2006). Promoter-specific mice show that the gene is being 
transcribed in the cell and the α1AAR subtype predominates in almost all regions (Papay et 
al., 2006, Table 1). Transgenic mice expressing both the endogenous mouse gene and a 
human α1BAR gene fused with EGFP were used to determine α1BAR localization (Papay et al., 
2004). These mice showed receptor protein expression in the cell rather than just 
transcribed RNA. α1BAR-EGFP mice confirmed expression of α1BARs in the thalamus though, 
in contrast to in situ studies, the level of expression was not specifically higher in the 
reticular thalamic nucleus (Papay et al., 2004; Zuscik et al., 2000). The α1BAR predominates 
in only the cerebral and piriform cortices and pontine nucleus of the hindbrain. In contrast 
to peripheral vessels, where the α1ARs regulate vasoconstriction, the cerebral blood vessels 
do not express either receptor subtype.  
Cellular Expression 
Cell types with α1AR subtype expression. The promoter-specific α1AAR-EGFP and 
protein-specific α1BAR-EGFP mice were used to determine co-labeling of each subtype with 
specific cell types. The α1AAR is transcribed in the cortex in NG2 oligodendrocytes, 
GABAergic interneurons, and NR1-containing cells; NR1 is a subunit of the NMDA receptor 
(Papay et al., 2006). In the hippocampus, α1AAR EGFP co-localizes with NR1 in the CA2 and 
CA3 The α1AAR is transcribed in the cortex in NG2 oligodendrocytes, GABAergic 
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TABLE 1. Distribution of the α1A- and α1BARs in the Brain (Adapted from Papay et al., 2006). 
_________________________________________________________________________
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Interneurons, and NR1-containing cells; NR1 is a subunit of the NMDA receptor (Papay et 
al., 2006). In the hippocampus, α1AAR EGFP co-localizes with NR1 in the CA2 and CA3 
regions and with GAD 65/67 in the dentate gyrus. They are also functionally expressed in 
somatostatin interneurons of the CA1 region (Hillman et al., 2007, 2005). The α1BAR also co-
localizes with NG2 positive oligodendrocytes in the cortex but is also expressed in neurons 
and CC1 cells (Papay et al., 2004). α1BAR expression coincides with granular, Purkinje, and 
molecular layer cells of the cerebellum.  
Determining localization of the receptors on the plasma membrane or internal was 
examined using co-immunoprecipitation. For in vivo confirmation, mice were created with a 
human α1AAR and EGFP both under the endogenous promoter (Papay et al., 2006). 
However, the endogenous signal is quite faint and amplification with GFP antibodies has 
been difficult. Additional methods have been employed to determine α1AR function. 
Methods to Study α1 Adrenergic Receptor Function 
Pharmacology 
α1ARs have been studied using pharmacological agents for decades. Several non-
selective α1AR agonists are used clinically. Phenylephrine is used to dilate pupils for eye 
exams and in some pathological conditions. Oxymetazoline is used in a nasal spray to 
reduce congestion by constricting the blood vessels in the sinuses. An adverse effect is that 
it causes rebound congestion due to receptor downregulation.  
Prazosin and doxazosin are non-selective α1AR antagonists used to reduce lower 
urinary tract symptoms in men with benign prostatic hyperplasia. Both are also sometimes 
used as a treatment for hypertension but only if the patient also suffers from lower urinary 
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tract symptoms. The adverse effects, mainly lightheadedness and faintness due to 
vasodilation preclude them from being front-line treatments for hypertension. 
Furthermore, non-selective α1AR antagonists given to patients with heart failure had worse 
outcomes in a clinical trial, forcing patients to be removed from that arm of the trial 
(ALLHAT, 2000). To circumvent the adverse effects caused by α1BAR blocking, selective 
α1AAR antagonists were created. These include siludosin and tamulosin and are the first line 
treatment for benign prostatic hyperplasia and lower urinary tract symptoms. All of the 
currently available clinical α1AAR agents are either too large or too hydrophilic to cross the 
blood brain barrier. Cirazoline is a full agonist at α1AARs and a partial agonist at α1B- and 
α1DARs (Horie et al., 1995). This provides a 5-8-fold selectivity for the α1AAR over the α1B- 
and α1DARs. However, cirazoline is not ideal because it also has α2AR antagonist properties 
(Ruffolo et al., 1982). Researchers addressed the lack of subtype-selective research drugs by 
creating transgenic animals to study the subtypes’ function. 
Transgenic 
Adrenergic receptor cloning allowed researchers to use cDNA to create mutant cells 
and transgenic animals, moving the field toward a better understanding of adrenergic 
receptor function. Transgenic models were created either without the receptor expressed 
(knockout, KO) or with a mutated form of the receptor holding it in its active conformation, 
mimicking an agonist effect.  
Knock-out models. The knock-out mice for all α1AR subtypes were originally created 
to study hypertension. The Antihypertensive and Lipid-Lowering Treatment to Prevent 
Heart Attack Trial (ALLHAT) showed that non-selective α1AR treatment worsens heart 
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failure in hypertension (ALLHAT, 2000). Further work using the following transgenic mouse 
models is helping to clarify the differing roles for each subtype in the peripheral and central 
nervous systems.  
The α1AAR gene was cloned from a 129/SvJ cDNA library (Rokosh and Simpson, 
2002). The Escherichia coli β-galactosidase gene, LacZ, and the neomycin-resistance gene 
replaced a large part of the gene’s first exon and part of the intron. The resulting mice were 
bred separately onto FVB/N and C57BL/6 backgrounds. α1AAR-KO have also mainly been 
used to study cardiac function and pathology (Reviewed in O’Connell et al., 2014 and Perez 
and Doze, 2011). Our lab is the only one to study central nervous system function using 
these mice. We showed α1AAR-KO is detrimental to learning and memory in the Barnes 
maze (Doze et al., 2011).  
α1BAR-KO mice were established using 129/Sv and BALB-c genomic libraries with 
hamster cDNA as a probe (Cavalli et al., 1997). Exon I of the α1BAR gene, derived from the 
129/Sv library, was replaced with the neomycin resistance gene, which codes for the first six 
transmembrane helices. The mice were originally bred as a 129Sv/ C57BL/6 hybrid but have 
since been backcrossed onto the C57BL/6 line, the most commonly used strain. α1BAR-KO 
mice have mainly been used to study cardiovascular and cardiac function (Reviewed in 
O’Connell et al., 2014 and Perez and Doze, 2011). One study thus far examined locomotion, 
learning and memory (Spreng et al., 2001).  
α1DAR-KO mice were generated using mouse cDNA (Tanoue et al., 2002). The α1DAR 
gene was replaced with the neomycin resistance gene and the resulting mice were a 129Sv/ 
C57BL/6J hybrid. The mice have been used to clarify the role of the α1DAR in 
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vasoconstriction and resulting effects on arterial blood pressure. Behavioral work shows 
that the α1DAR impairs working memory and attention but not spatial memory (Mishima et 
al., 2004). In addition, MK-801, an NMDA receptor antagonist, induces deficits in the 
acoustic startle reflex but this effect was blocked in α1DAR-KO mice.  
Double α1A/BAR-KO mice were created by breeding α1AAR-KO (FVB, 129Sv) mice with 
α1BAR-KO mice (C57BL/6, 129Sv) (O’Connell et al., 2003). F1 heterozygotes were bred to 
produce WT and A/B-KO; breeding pairs from the lines were established. The double A/B-
KO mice are used to study cardiac function including the role of the α1A in cardiac apoptosis 
(Huang et al., 2007).  
Double α1B/DAR-KO mice were produced by breeding of single α1B- and α1DAR-KO 
mice which were of mixed 129Sv and C57BL/6J backgrounds (Hosoda et al., 2005). These 
mice were also used to study blood pressure regulation. 
Activation models. Transgenic models of α1AR subtype activation were also 
established and utilized for the study of cardiac function. Activation models include low (2x) 
to high level (66x) overexpression with or without constitutive activity.  
CAM-α1AAR mice have a constitutively active mutant form of the rat α1AAR under the 
control of the mouse α1AAR promoter (Rorabaugh et al., 2005). Constitutive activity is 
conferred by two mutations: M292L and A271E, and results in 3.5-fold overactivity based on 
IP3 levels. CAM-α1AAR mice have improved survival due to heart failure after myocardial 
infarction in addition to other cardiac benefits (Du et al., 2006). Previously, we showed that 
CAM-α1AAR mice have lower levels of depression and anxiety, enhanced learning and 
memory, and live longer than WT mice (Doze et al., 2009, 2011).  
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An α1BAR model of activation was achieved by expressing a constitutively active 
mutant form of the hamster α1B-AR under the endogenous mouse α1BAR promoter (Zuscik 
et al., 2000). Constitutive activity was achieved by mutating three residues: 
C128F/A204V/A293E. The triple mutant receptor spontaneously couples to Gq without an 
agonist present conferring a 4-fold overactivity based on IP3 levels. These mice were initially 
called T1 mice but later changed to CAM-α1BAR mice to more easily identify the transgenic 
changes (Yun et al., 2003; Doze et al., 2009). In the cardiovascular system, CAM-α1BAR mice 
have faster progression to heart failure with pressure overload and a pathological cardiac 
hypertrophy (Wang et al., 2000; Zuscik et al., 2001). Surprisingly, CAM-α1BAR mice also have 
a synucleinopathy, progressive neurodegeneration, and locomotion impairments (Zuscik et 
al., 2000).  
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CHAPTER 2:  
ALPHA1A OR ALPHA1B ADRENERGIC RECEPTOR KNOCKOUT DOES NOT IMPAIR NOVEL 
OBJECT RECOGNITION, SPATIAL LEARNING AND MEMORY, OR PATTERN SEPARATION 
 
Abstract 
Norepinephrine, which binds to adrenergic receptors, has a clear role in arousal and 
vigilance, which can enhance performance on cognitive tasks. The role of the α1 adrenergic 
receptor subtypes in learning and memory, however, is unclear as research shows 
conflicting results. Chronic activation of the α1AAR subtype improves learning and memory 
performance in the Barnes and multi-t mazes. Knockout of the α1AAR impairs performance 
in the Barnes maze. The α1BAR subtype has rarely been studied in the context of cognition. 
In the current study, we examined the role of the α1AR subtypes, α1A- and α1BAR, on novel 
object recognition, spontaneous alternation in the t-maze, and spatial learning, memory, 
and pattern separation in the Morris water maze. We found that α1A- and α1BAR-KO mice 
may have impaired object recognition memory; however, preference for one of the objects 
may have confounded the results. Unreliable performance by wild type mice precluded 
definitive conclusions for the role of the subtypes in spontaneous alternation. In the Morris 
water maze, α1AAR-KO mice did not form an efficient path to the platform but were normal 
in latency and distance to reach the platform. All groups learned spatial strategies to solve 
the maze. Based on our previous work in α1AAR activation and knockout mice, and the 
potential confounding variables in the present study, we suggest further research into the 
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role of the α1AAR in cognition. Similarly, the role for the α1BAR receptor was not clarified in 
the current study and should be further examined.  
Introduction 
Noradrenergic fibers project from the locus coeruleus to virtually every region of the 
brain, where they release the neurotransmitter norepinephrine. Norepinephrine is well 
known for its enhancing effects on arousal and vigilance (Reviewed in Sirviö and 
MacDonald, 1999). It has a role in plasticity, memory formation, consolidation, retrieval, 
and working memory (Izumi and Zorumski, 1999; Segal et al., 1991; Sara and Devauges, 
1988; Murchison et al., 2004). However, the mechanisms are complex, partly due to 
multiple adrenergic receptors. Norepinephrine binds to three families of G-protein coupled 
adrenergic receptors (ARs), α1, α2, and β, each with three subtypes (Figure 6). The subtypes 
are expressed at different levels in various brain regions. Recent evidence suggests the 
involvement of norepinephrine in learning and memory is dependent on the receptor 
families and subtypes.  
The α1ARs are involved in learning and memory but whether the effect is an 
enhancement or detrimental is controversial. Norepinephrine, via α1ARs inhibits memory 
consolidation in the chick at high doses of the α1AR agonist methoxamine but enhances it at 
lower doses, potentially via astrocytic α1ARs (Gibbs and Summers, 2001; Gibbs and Bowser, 
2010). Arnsten’s group found that α1ARs impair performance on prefrontal cortex-
dependent tasks while α2ARs enhance it (Reviewed in Ramos and Arnsten, 2007). They also 
found impaired performance at a low dose of the α1AAR agonist, cirazoline, and enhanced 
performance at a higher dose known to block imidazoline and α2ARs (Arnsten and Jentsch, 
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Figure 6. Adrenergic receptor subtypes. 
 
1997). In contrast, microinjection of the α1AR agonist phenylephrine into the CA1 region of 
the hippocampus improves acquisition in the Morris water maze; the α1AR antagonist 
prazosin, an α1AR antagonist, had the opposite effect (Torkaman-Boutorabi et al., 2014). 
Prazosin impaired performance in the Morris water maze in one study but had no effect in 
another (Puumala et al., 1998; Riekkinen et al., 1996). The drug ST-587 was originally 
thought to be selective for the α1AR and improved learning in cognition-based experiments 
but was later found to be non-selective (Puumala et al., 1996; Puumala and Sirviö, 1997; 
Pussinen and Sirviö, 1998). Many studies examining the role of α1ARs used acute 
administration of non-subtype selective drugs.   
The generation of transgenic mice with α1AR subtype activation or knockout (KO) 
properties greatly enhanced the ability to study the role of the receptor subtypes in 
behavior. The α1AAR subtype, via transgenic or chronic pharmacological activation, 
enhances spatial learning and memory in the Barnes and multi-t mazes (Doze et al., 2011). 
Transgenic activation also enhances learning and memory in the Morris water maze and 
long-term potentiation in the CA1 region of the hippocampus. Knockout of the α1AAR 
subtype impairs performance in the Barnes maze. The lack of learning and memory studies 
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using α1AAR-KO mice is likely impaired by the incidence of seizures in these mice (Doze and 
Collette, unpublished observation). Therefore, seizure activity was taken into account in our 
study. Knockout of the α1BAR subtype enhanced novel object recognition and impaired 
spatial memory in the Morris water maze but no other reports on the α1BAR and learning 
and memory have been published (Spreng et al., 2001). 
Based on the conflicting results for the role of α1ARs in cognition, and the dearth of 
studies on the α1BAR subtype in learning and memory, additional research was warranted. 
Based on our previous results of α1AAR subtype activation, we hypothesized that α1AAR-KO 
mice would have impaired learning and memory for hippocampal-specific learning and 
memory tasks. Based on the Spreng et al. study, we expected α1BAR-KO to have enhanced 
object recognition memory and impaired spatial memory in the Morris water maze when 
compared with wild type mice.  
Methods 
Animals 
Mice were bred and genotyped at the Cleveland Clinic Foundation then transferred 
to the University of North Dakota at 3-4 mo of age. Mice were provided standard chow with 
5% fat (Teklad 22/5 Rodent Diet (W) 8640, Harlan, Indianapolis, IN) and water ad libitum, 
were maintained on a 12-hr light cycle (on at 0700), and provided veterinary care. α1A- and 
α1BAR-KO mice have been previously characterized (Rokosh and Simpson, 2002; Cavalli et 
al., 1997). Control animals (n = 13), were wild type (WT) littermates of the α1A- (n = 22) and 
α1BAR (n = 14) KO lines. α1AAR-KO mice were of the F7-F9 generation while α1BAR-KO mice 
were all of the F9 generation. There were approximately equal numbers of male and female 
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animals. All protocols conformed to the Guide for the Care and Use of Laboratory Animals 
and were approved by the Institutional Animal Care and Use Committee at the University of 
North Dakota. The facilities at the Cleveland Clinic Foundation and the University of North 
Dakota are both accredited by the Association for Assessment and Accreditation of 
Laboratory Animal Care.  
Seizure Incidence 
The incidence of seizures was noted anytime the mice were observed, mainly prior 
to and during behavioral testing. Seizures were identified as a binary (yes or no) outcome 
(McKhann et al., 2003). Seizures were not classified by stage. However, informal 
observation indicated that seizures included Stages 1-3, immobility, rigidity, and head 
bobbing. No notes indicate that seizures progressed to Stages 4-6, intermittent or 
continuous rearing and falling or whole body convulsions. 
Data for novel object recognition and t-maze were analyzed to determine if seizure 
occurrence affected performance in the tests. Handling of seizure occurrence during the 
Morris water maze is detailed in the Statistical Analysis portion of these Methods.    
General Health and Neurological Assessments 
The mice were assessed for general health and neurological reflexes as per a 
protocol provided by Dr. Maria Gulinello at Albert Einstein College of Medicine, which is 
based on the SHIRPA protocol (Rogers et al., 1997). General health was assessed by 
observing nesting and home cage activity, aggression, coat condition, piloerection, whisker 
quality, body weight, and body temperature. Most other parameters were assessed in a 
82.0 x 51.8 x 42.4 cm (31 gal) container (Newell Rubbermaid, Atlanta, GA) with a grid of 8 
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squares drawn across the bottom. Activity/ arousal was assessed by how fast the animal 
moved from its initial position to cross the first gridline (transfer arousal); number of 
gridline crossings, rearings, and stretch attend postures; response to touch; positional 
passivity; and a gross measure of startle response which involved snapping a mouse trap 
above the container. Motor and autonomic function assessment involved abdominal 
elevation, paw position (width and pronation), gait, righting reflex, ataxia, and balance 
beam slips. The balance beam consisted of a wooden dowel with marks 7.6 cm apart 
secured lengthwise in a second 31 gal container. The number of balance beam slips within 
passing 10 marks on the dowel was used to assess motor skills and balance. Also in the 
second container, a 0.48 cm diameter rope was secured across the box lengthwise, upon 
which the animals were placed holding the rope with their front paws. The time before the 
mice lost their grip and fell was measured three times and averaged. Sensory reflex function 
was assessed by response to toe pinch, negative geotaxis, vision, pinna, whisker, and 
provoked biting.  
Behavioral Testing 
Behavioral testing of learning and memory occurred between 0800 and 1230. The 
experimental timeline includes the zero maze, which took place between 1200 and 1700, 
but the results were reported elsewhere (Figure 7). Testing for each mouse was set at least 
24 hr apart. Mice were approximately 5 mo of age at the start of behavioral testing. Mice 
were acclimated to separate cages for 30 min prior to all tests except the general health and 
neurological assessment, which was performed directly from the home cage. Equipment 
was cleaned with 10 percent ethanol between each mouse. 
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Figure 7. Behavioral testing timeline. The zero maze results were reported in a separate study. 
Testing began when mice were 4 mo of age.  
 
Novel object recognition. In the first phase of the novel object recognition test, 
habituation, the animals were placed in an empty 40 x 40 x 35 cm open field box for 5 min 
(Stoelting, Wood Dale, IL). After one hour, the mice were returned to the open field for a 5 
min familiarization phase. During this second phase, the open field contained two identical 
objects, which were counterbalanced to avoid object bias. The objects were 5.08 cm tall 
white pointed columns with a black stripe near the top or 4.13 cm black spheres (Figure 8, 
Lahud Craftsmen LLC, Fertile, MN; Stoelting, Wood Dale, IL). After another hour, the testing 
phase began. Mice were placed back in the open field with their respective original object 
(OO) and the novel object (NO). The time spent with each object was used to calculate the 
discrimination index and the percent of exploration time spent with the novel object. The 
discrimination index used the equation: [(time with OO - time with NO)/ (time with OO + 
time with NO)]. Habituation to the objects was determined by comparing the time spent 
exploring the original object during the familiarization phase and testing phase.   
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Figure 8. Novel object recognition objects. The objects used in the novel object recognition test 
included a black sphere and a white pointed column with a black horizontal stripe near the top.  
 
T-maze. The t-maze was used to test for spontaneous alternation, a form of short-
term memory. The t-maze apparatus was made with white melamine particle board with 
removable walls 12.7 cm in height (Figure 9). Mice were placed on the maze at the bottom 
of the T and were allowed to choose the left or right arm. The walls of the maze were lifted 
and the animal was placed back at the starting point. Each mouse received 5 trials and the 
percent of alternations was used for analysis. 
Morris water maze. The Morris water maze was used to test spatial learning and 
pattern separation, via a reversal paradigm. The maze consisted of a circular tank 122 cm in 
diameter and 76 cm in depth (San Diego Instruments, San Diego, CA). The top of a 10 cm 
square platform was 25 cm from the top of the tank and room temperature water tinted 
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Figure 9. T-maze dimensions. The t-maze was used to test spontaneous alternation. 
 
with Art Minds white non-toxic tempera paint covered the platform by 1 cm (Michaels 
Stores Inc, Irving, TX). The tank was enclosed within a 152 x 152 cm grey tent (Ace Canopy, 
Palmdale, CA). Distal spatial cues included a folded step ladder, a black cardboard circle 21.5 
cm in diameter taped to a wall of the tent, a white lamp, and one side of the tent open to 
the room. The experimenter was blocked from view of the mice during all trials. The search 
area:target area ratio was 117:1, ideal for testing mice (Vorhees and Williams, 2006). The 
platform location was counterbalanced equally within groups. 
Mice were trained for 6 trials per day over 3 days. On Day 4, the platform location 
was reversed and stayed in the reversal position on Day 5. Starting positions were chosen 
using a pseudorandom algorithm and changed for each trial. AnyMaze software and a 
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Logitech web camera were used to digitally control and record the trials (Stoelting Co., 
Wood Dale, IL). The maximum allotted time for each trial was 120 s and mice were 
considered by the software to have arrived on the platform if they were in the platform 
zone for 2 s. They were allowed to remain on the platform for 30 s. If mice did not find the 
platform, they were guided there using a plastic ruler and allowed to remain for 30 s. 
Following each trial, mice were lightly dried with a towel and placed under a heat lamp until 
the next trial, while other mice were tested. The inter-trial interval ranged from 5-10 min. 
On Day 4, the platform location was reversed to test pattern separation. The platform 
remained in this second location on Day 5. Qualitative strategies were analyzed using a 
modified MATLAB script generously provided by Gerd Kempermann and Alexander Garthe 
(Garthe et al., 2009).  
Statistical Analysis 
Statistical analyses were performed using GraphPad Prism 5.04 (GraphPad Software, 
San Diego, CA). Normality was assessed using the Kolmogorov-Smirnov test. Variances were 
assessed using the Bartlett’s test and non-parametric tests were used if the variances were 
significantly different. Significant outliers, found using the Grubb’s test, were excluded. One 
way ANOVA, with a Tukey post-hoc test, was used to assess differences between groups 
even if the data were non-normal because ANOVA is robust for violations of normality. One-
sample t-tests were used to assess significant deviations from chance levels in the novel 
object recognition and t-maze tasks. Sex differences were assessed with a 2 way ANOVA 
with genotype X sex and a Bonferroni post-test for paired comparisons. Trial data missing 
due to technological error or, in the case of α1AAR-KO mice a seizure in the maze, were 
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interpolated by taking the mean of the previous and next trial. Two mice were excluded 
from the study early due to a high number of seizures in the maze. Morris water maze data 
were analyzed using 2 way ANOVAs of genotype X day, genotype X trial, and trial X 
genotype, and day X genotype. 
Results 
General Health and Neurological Assessments 
There were no group differences in any of the general health assessment 
parameters, including body weight and temperature, transfer arousal, grid crossings, 
rearings, or stretch attend postures. In another study, there were no differences in basal 
locomotion in the open field test (Chapter 2).There were no obvious differences in the 
qualitative assessment of neurological reflexes.  
Novel Object Recognition 
The variances between group means in the time spent with the NO differed 
significantly; therefore, the non-parametric Kruskal-Wallis test was used for analysis. There 
was a main effect of time spent with the NO (χ2(2) = 8.74, p = 0.01). A Dunn’s post-hoc test 
revealed that α1AAR-KO mice spent less time with the novel object than α1BAR-KO mice (p < 
0.05) but not less than WT mice (p > 0.05).  
When taking into account the total time spent exploring objects, there was no 
significant difference between groups in the percentage of time spent with the NO [F(2, 38) 
= 0.47, p = 0.62, Figure 10A]. There were no sex differences in the percent of time spent 
with the NO [F(1, 35) = 1.09, p = 0.30]. There was also no difference between α1AAR-KO 
mice that did not have seizures (n = 7) and mice that did (n = 9), [t(14) = 1.17, p = 0.25]. 
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Figure 10. Novel object recognition. A) α1AAR-KO mice spent less time with the NO then α1BAR-KO (p 
< 0.05) but not WT mice (p > 0.05). B) WT mice spent a higher than chance level percentage of time 
with the NO (p < 0.05), while α1AAR-KO and α1BAR-KO mice did not. C) All groups spent a higher than 
chance level percentage of time with the pointed column. D) All groups habituated to the black 
sphere as an original object but not to the pointed column. *p < 0.05 
 
A one-sample t-test showed that WT mice spent a higher than chance percentage of 
time with the NO (50 percent) (p = 0.01), while α1AAR-KO (p = 0.05) and α1BAR-KO (p = 0.32) 
mice did not (Figure 10B). This shows that WT mice remembered the NO while the KO mice 
did not. 
Further analysis revealed that each group spent a higher than chance percentage of 
time with the pointed column (Figure 10 C). All groups habituated to the black sphere when 
it was the original object, WT (p = 0.01), α1AAR (p = 0.01), and α1BAR-KO (p = 0.03) (Figure 
5D). However, when the pointed column was the original object, WT (p = 0.44), α1AAR (p = 
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0.25), and α1BAR-KO (p = 0.94) mice spent a chance level of time with it during the testing 
phase, suggesting no habituation (Figure 10D). This implies all groups preferred the pointed 
column during the testing phase, even when it had been the original object. Two way 
ANOVAs for this data showed no main effect of genotype, a main effect of object, but no 
post-hoc differences (Genotype: F(2, 35) = 0.65, p = 0.52, Object: F(1, 35) = 13.29, p 
<0.0009). 
T-maze 
In the t-maze for spontaneous alternation, there was no difference between groups 
for the percent of alternations [F(2, 43) = 0.73, p = 0.48, Figure 11]. The Wilcoxon signed 
rank test, for non-normally distributed data, showed that no group performed better than 
chance levels (50 percent correct). There were no differences in the percentage of 
alternations between mice that had seizures and mice that did not [t(17) = 0.68, p = 0.50]. 
Mice that had seizures and mice that did not have seizures performed at chance levels. 
Morris Water Maze 
Learning, Days 1-3. For latency to reach the platform, there was a main effect of 
training days [F(4, 140) = 30.25, p < 0.0001] but no effect of genotype [F(2, 140) = 1.10, p = 
0.34, Figures 12A and 12B]. All three groups decreased the latency to reach the platform by 
Day 2: WT (p < 0.001), α1AAR-KO (p < 0.0001), and α1BAR-KO (p < 0.001).  
Distance to reach the platform also showed a main effect of days, [F(4, 140) = 29.00, 
p < 0.0001] but no effect of genotype [F(2, 140) = 2.78, p = 0.07, Figures 12C and 12D]. All 
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Figure 11. T-maze. In the t-maze, none of the groups alternated a higher than chance percentage of 
times (p > 0.05). There were no group differences in the percentage of alternations.  
 
groups decreased the distance it took to reach the platform by Day 2: WT (p < 0.001), 
α1AAR-KO (p < 0.01), and α1BAR-KO (p < 0.001).  
Path efficiency showed a main effect of training days [F(4, 140) = 11.69, p < 0.0001]; 
however, no effect of genotype was found [F(2, 140) = 0.81, p = 0.44, Figures 12E and 12F]. 
Post-hoc testing revealed that WT (p < 0.05) and α1BAR-KO mice (p < 0.01) increased  
efficiency to the platform by Day 3. α1AAR-KO mice did not significantly increase path 
efficiency until Day 5 (p < 0.001). For swim speed, there was no main effect of days [F(4, 
140) = 0.99, p = 0.41]; however, there was an effect of genotype [F(2, 140) = 3.97, p = 0.02, 
Figures 12G and 12H]. Post-hoc testing showed that α1AAR-KO mice swam slower when 
compared with WT mice on Day 1 (p < 0.05) and Day 2 (p < 0.05). However, there was also 
an interaction between genotype and day of testing [F(8, 140) = 3.30, p = 0.001], which 
makes this result difficult to interpret. The slight differences between swim speed (0.02 m/s 
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or 2 cm/s) likely were not relevant to interpretation of other factors based on speed, such 
as latency. 
The combined results suggest that all groups learned the location of the platform by 
Day 2. However, α1AAR-KO mice did not learn to use a more efficient path to the platform 
during the three-day training period.  
Reversal learning, Days 4-5. The α1AARs are highly expressed in the dentate gyrus, 
an area of the hippocampus important for pattern separation, which can be tested in a 
reversal paradigm of the Morris water maze (Sahay et al., 2011; Aimone et al., 2011; Piatti 
et al., 2013; Garthe et al., 2009). In this protocol, the location of the platform is changed but 
the spatial cues remain the same. The mice must learn the new location of the platform by 
using spatial information learned in the first phase of training.  
As reported in the previous section, there were no main effects of genotype on any 
of the days of testing for latency, distance traveled, or path efficiency to the platform. There 
was a main effect of swim speed, reported above; however, it was limited to Day 1 and Day 
2 of testing between WT and α1AAR-KO.  
Overall, the reversal protocol did not significantly change pattern separation in any 
of the groups. Interestingly, the α1AAR-KO mice improved path efficiency by Day 5. One 
reason the path efficiency may not have improved in this group could be due to the use of 
non-spatial search strategies.  
Search strategies. Rodents use both non-spatial and spatial search strategies while 
learning the location of a platform in the Morris water maze. Initially, searching is through 
non-spatial means which tend to follow a pattern. Garthe, Behr, and Kempermann
36 
 
Figure 12. Morris water maze. A) WT (p < 0.001), α1AAR-KO (p < 0.0001), and α1BAR-KO mice (p < 
0.001) reduced the latency to reach the platform by Day 2 of training but B) there were no 
differences between genotype. C) WT (p < 0.001), α1AAR-KO (p < 0.01), and α1BAR-KO mice (p < 
0.001) reduced the distance traveled to the platform by Day 2 of training but D) there were no 
differences between genotype. E) WT (p < 0.05) and α1BAR-KO mice (p < 0.01) increased path 
efficiency to the platform by Day 3 while α1AAR-KO did not even after 5 days (p > 0.05) and F) there 
were no between group differences. G/H) α1AAR-KO mice swam slower than WT mice on Day 1 (p < 
0.05) and Day 2 (p < 0.05).  Platform reversal, *p < 0.05, **p < 0.01, ***p < 0.001), ****p < 0.0001 
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developed an algorithm to assess search strategies (Garthe et al., 2009, Figure 13). Mice 
often begin searching by hugging the walls of the maze, a tactic called thigmotaxis. Mice 
also search randomly then progress to searching in the general area of the platform. After 
several trials, the strategies begin to follow spatially oriented patterns including chaining, 
which is when the mouse swims at a distance from the wall equal to the diameter of the 
platform location. In the last part of learning, mice use spatial approaches such as directed 
search, focal search, and direct swimming to the platform. During a platform reversal 
paradigm, mice will persevere at the original platform location then default to non-spatial 
strategies but quickly switch back to spatial strategies by the second day of training. We 
utilized a MATLAB script kindly provided by the Kempermann lab to assess search 
strategies. Mice performed as expected, first using non-spatial strategies and gradually 
switching to spatial strategies (Figure 14A). 
There was a main effect of days [F(4, 140) = 14.90, p < 0.0001] but not genotype 
[F(2, 140) = 0.91, p = 0.41] for the percent of spatial strategies used (Figure 14B). Post-hoc 
testing showed that α1BAR-KO mice significantly increased the use of spatial strategies by 
Day 2, while WT and α1AAR-KO mice did not do so until Day 3. As expected on Day 4 after 
platform reversal, WT mice significantly decreased the use of spatial strategies (p < 0.001). 
Surprisingly, α1AAR-KO (p > 0.05) and α1BAR-KO mice (p > 0.05) did not show a significant 
decrease in spatial strategy use upon platform reversal. None of the groups showed a
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Figure 13. Search strategies in the Morris water maze. Adapted from (Garthe et al., 2009). A) The 
Morris water maze was divided into a wider wall zone closest to the wall of the maze, a closer wall 
zone, an annulus zone around the diameters of the inner and outer platform corners, and a center 
zone. A MATLAB algorithm was used to determine search strategies.  
 
significant increase in the use of spatial strategies on Day 5. All groups showed 
perseverance to the original platform location on Day 4 but there was not a significant 
decrease in perseverance on Day 5 [F(1, 35) = 3.95, p = 0.05, Figure 14C]. In the cued trial on 
Day 5, there were no differences in latency [F(2, 31) = 8.71, p = 0.61], distance traveled [F(2, 
32) = 0.79, p = 0.36], or swim speed [F(2, 34) = 0.002, p = 0.15].  
Overall, WT mice performed as expected in the Morris water maze with regards to 
search strategies but there were no differences between genotypes in either search 
strategy or perseverance.  
 
40 
 
Figure 14. Spatial and non-spatial strategies in the Morris water maze. A) WT, α1AAR-KO, and α1BAR-
KO mice followed a typical progression from non-spatial to spatial search strategies while learning 
the location of the platform. B) WT mice significantly increased the use of spatial strategies by Day 3 
of training (p < 0.01) and decreased the use of spatial strategies on platform reversal Day 4 (p < 
0.001). α1AAR-KO mice increased the used of spatial strategies by Day 3 of training (p < 0.001) but 
did not significantly decrease their use upon platform reversal. α1BAR-KO mice increased the use of 
spatial strategies by Day 2 of training (p < 0.05) but did not decrease their use on platform reversal 
Day 4. C) All groups persevered at the previous platform location on Day 4 but did not significantly 
decrease the amount of perseverance by Day 5.
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Discussion 
The current study found no difference in general health or neurological reflexes 
between groups. A previous experiment from our lab showed no difference in locomotion 
in the open field test (Chapter 2). 
Previous studies of the α1ARs found conflicting results in learning and memory tasks, 
likely due to differential effects of the α1AAR and α1BAR subtypes. Our lab showed that 
α1AAR stimulation via pharmacological or transgenic means enhances spatial learning and  
memory (Doze et al., 2011). In the same study, α1AAR-KO impaired both learning and 
memory in the Barnes maze. The only published research regarding the role of the α1BAR 
subtype in cognition showed that transgenic mice lacking the α1BAR have enhanced novel 
object recognition but impaired performance in the Morris water maze (Spreng et al., 
2001).  
In the novel object recognition test, α1AAR-KO mice spent less time with the NO 
impaired when compared with α1BAR-KO but not WT mice. WT mice were the only group to 
spend a greater than chance percentage of time with the novel object but there were no 
differences between groups. Comparing performance to chance levels is an indicator of 
whether the test worked because WT mice should do better than chance levels at 
recognizing the NO. That neither KO group did better than chance suggests impaired 
memory in both groups but the results could be confounded by the preference for a 
particular object. The objects used were counterbalanced but none of the groups 
habituated to the pointed column, suggesting they preferred it whether it was the original 
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or novel object. In order to avoid object bias, a greater number of animals or objects should 
be assessed with cohorts of WT mice prior to use in the novel object recognition test.   
In the spontaneous alternation version of the t-maze, WT mice generally show 
greater than 80 percent alternation (Deacon and Rawlins, 2006). In the current study, WT 
mice did not alternate at a level higher than chance (50 percent). This could be due to the 
short (0 s) intra-trial interval, the amount of time mice were confined to the chosen arm 
prior to the next trial (Lalonde, 2002). The intra-trial interval is when memories are 
encoded; therefore, a longer interval may have enhanced the memory of the previously 
chosen arm. Typically, each trial should take less than 2 min; however, some mice took 
much longer. It is possible the short intra-trial interval increased anxiety leading to 
hesitancy to explore.  
Previous research on the α1AR showed that prazosin, a non-subtype selective α1AR 
antagonist, can either impair or improve cognitive performance in the Morris water maze 
(Riekkinen et al., 1996). In the Morris water maze, all mice decreased the latency and the 
distance traveled to the platform by Day 2. WT and α1BAR-KO mice increased their path 
efficiency by Day 3 but α1AAR-KO did not, even by the final day of testing. The platform 
reversal did not significantly increase difficulty for mice to solve the maze on Day 4. 
However, WT mice did significantly reduce the use of spatial strategies on Day 4.   
A high dose of prazosin can increase the time to complete a cued trial, suggesting a 
slower swimming speed (Riekkinen et al., 1996). In another study, α1BAR-KO mice had 
decreased swimming speed (Spreng et al., 2001). Surprisingly, in the current study α1AAR-KO 
but not α1BAR-KO showed a decreased swim speed during testing but all groups swam the 
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same speed during the cued trial. The decrease in swim speed during testing was significant 
but not large therefore it is not necessarily biologically relevant. 
These results combined suggest there may be deficits in novel object recognition for 
both α1AAR-KO and α1BAR-KO mice but spatial memory impairment only in α1AAR-KO mice 
based on a lack of increased path efficiency. Further research is important because α1AAR-
KO mice performed well on all other measures in the Morris water maze. Future testing 
should include another measure of spatial memory, such as the radial arm maze or a spatial 
cue version of the t-maze, both of which require food restriction. It appears that the α1AAR 
is important for spatial memory based on our CAM-α1AAR mouse studies so it is interesting 
but not wholly unexpected that knock-out did not cause severe impairments. Compensation 
in KO mice is a common limitation and can be avoided using the Cre lox system for 
conditional KO. Barring that, the use of an α1AAR antagonist via a cannula could also help 
clarify the role of the α1AAR in learning and memory.  
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CHAPTER 3  
ALPHA1B ADRENERGIC RECEPTOR KNOCKOUT DECREASES DEPRESSION-LIKE BEHAVIOR 
WHILE KNOCKOUT OF EITHER THE ALPHA1AAR OR ALPHA1BAR DO NOT RELIABLY AFFECT 
ANXIETY 
 
Abstract 
Blocking neurotransmitter uptake via the norepinephrine transporter has long been 
a target of antidepressants. The role of the adrenergic receptors in the treatment or 
etiology of depression and anxiety has not been clearly defined. Previous research showed 
that chronic activation of the α1AAR subtype leads to a lower level of depression-like 
behavior in the tail suspension test while activation of the α1BAR subtype leads to a higher 
level. In the present study, we further investigated the involvement of the α1AR subtypes, 
α1AAR and α1BAR, in depression and anxiety-like behavior in the adult mouse. We used two 
cohorts of subtype-specific receptor knockout (KO) mice. Group 1 mice began testing at 155 
d and Group 2 at 90 d of age. Because α1AAR-KO mice have seizures, we addressed seizure 
occurrence in the analysis. We found that α1AAR-KO mice had higher levels of anxiety in 
Group 1 mice compared with wild type (WT), after accounting for seizure incidence. 
However, there was no change in Group 2 α1AAR-KO mice in either anxiety or depression 
compared with WT mice. Lack of α1BAR showed a lower depression-like phenotype 
compared with WT mice but had no change on anxiety in Group 1 mice and unclear results 
in Group 2 mice. We conclude that the role of the α1AR subtypes in anxiety behavior is
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complex. Combined with our previous results regarding α1AR subtype activation, it is likely 
the α1AAR is involved in alleviating depression. Based on previous and the current results, 
the α1BAR subtype is clearly involved in depression-like behavior in the mouse. These results 
suggest the α1AR subtypes may be therapeutic targets for depression. A drug with α1AAR 
agonist and α1BAR antagonist properties may be ideal. 
Introduction 
Major depressive disorder affects 16 percent of the United States population at least 
once in their lifetime and has an economic burden of $80 billion per year (Kessler et al., 
2003; Wang et al., 2003).  According to the 2012 National Survey on Drug Use and Health, 
almost 7 percent of adults in the US had at least one depressive episode in the previous 
year (Hedden et al., 2013). Yet currently available treatments are not ideal. Fifty percent of 
patients with major depression have only a moderate response to currently available 
antidepressants and just 30 percent find full remission (Trivedi et al., 2006). Norepinephrine 
(NE) and serotonin (5-HT) were the first neurotransmitters found to alleviate depressive 
symptoms and are still the leading targets for current antidepressants. Most treatments are 
based on blocking reuptake of 5-HT and/or NE; however, many of these antidepressants 
also have antagonist actions at 5-HT, α adrenergic, and dopamine receptors. Despite this, 
the evidence for an antidepressant effect based on agonist activity at an α1 adrenergic 
receptor (α1AR) subtype, the α1AAR, has been mounting.  
Many serotonin selective reuptake inhibitors (SSRIs) and serotonin norepinephrine 
reuptake inhibitors (SNRIs) are used clinically for both depression and anxiety, which are 
often comorbid (Kessler et al., 2003). Milnacipran, an SNRI, activates the α1AR in rat 
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organotypic raphe slice cultures in addition to its blockade of NE and 5-HT reuptake 
(Nagayasu et al., 2013). α1AR antagonists can block anxiety and depressive behavior in 
animal models (Kitada et al., 1983; Danysz et al., 1986; Cunha et al., 2013; Stone et al., 
2011; Kakui et al., 2009). The α1AR inverse agonist prazosin reverses the anti-immobility 
effect of paroxetine and citalopram, both SSRIs, in the forced swim test (Sugimoto et al., 
2011; Izumi et al., 1997). α1- and α2AR antagonists show a similar effect with the mood 
stabilizer lamotrigine (Kaster et al., 2007). When the α1AR agonist phenylephrine and 
lamotrigine were given at sub-effective doses the antidepressant action was potentiated. 
Prazosin also increases latency to enter the dark compartment in the passive avoidance task 
suggesting α1ARs are involved in anxiety as well (Puumala et al., 1996). A  blockade of 
antidepressant behavior was not seen in other studies using α1AR antagonists with 7 d of 
treatment with desipramine, a tricyclic antidepressant blocking reuptake of NE (Borsini et 
al., 1984; Pulvirenti and Samanin, 1986). However, these studies used non-subtype selective 
agonists and antagonists. Recent evidence from our lab suggests subtype selective 
activation is critical for behavioral effects.  
The α1AAR subtype is affected by chronic antidepressant treatment and 
electroconvulsive therapy (Nalepa et al., 2002). Both increase the density and activity of 
α1AARs in the frontal cortex and hippocampus without changing mRNA levels. Increased 
density of receptors can cause increased sensitivity to the ligand translating into an 
enhanced downstream effect. Desipramine increases the α1AAR to α1BAR ratio in rat 
cerebral cortex (Hanft and Gross, 1990). Repeated electroconvulsive therapy also increases 
binding to the α1BAR in the cortex, thalamus, and amygdala; however, most of the binding 
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in the lateral amygdala was to α1AARs (Perry et al., 1990). Creation of transgenic mice either 
overexpressing or knocking out the α1AAR and α1BAR subtypes has provided the opportunity 
to further define the role of the subtypes in mood behavior.  
Our lab found that activation of the α1AAR and α1BAR has differential effects on 
depressive-like behavior in the mouse (Doze et al., 2009). Mice with a constitutively active 
mutant form of the α1AAR (CAM-α1AAR) have increased agonist affinity and activation of the 
receptor. This provides an antidepressant and anxiolytic effect. However, CAM-α1BAR mice 
have higher depression-like behavior but no change in anxiety (Doze et al., 2009, 2011).  
We hypothesized that α1AAR-KO mice would exhibit greater depression and anxiety-
like behaviors than wild type (WT) mice. We also hypothesized that α1BAR-KO mice would 
have a lower level of depression-like behavior but not anxiety behavior when compared 
with WT mice. To test this, we examined depression and anxiety behavior using the tail 
suspension test, elevated zero maze, marble burying test, and light dark exploration in 
Group 2 mice. Due to seizure activity appearing to be age-related, we also investigated 
anxiety behavior in Group 1 mice in the open field (center time) and the elevated zero 
maze.   
The current study is the first to examine the effect of α1AAR-KO and α1BAR-KO on 
anxiety and depression-like behavior. Mice lacking each receptor subtype have been 
previously studied in the context of cardiac function, learning, and memory. In addition, 
seizure activity in the α1AAR-KO mice has not been reported. The lack of behavioral studies 
is potentially due to this seizure activity, which makes analysis challenging (Doze et al., 
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unpublished observation). Thus, we considered the incidence of seizures in our analysis and 
found interesting results. 
Methods 
Animals 
All animals were bred and genotyped at the Cleveland Clinic Foundation and 
transferred to the University of North Dakota at 2 or 4 mo of age. Both facilities are 
accredited by the Association for Assessment and Accreditation of Laboratory Animal Care. 
The 4 mo old mice comprised Group 1 and included 15 WT, 17 α1AAR-, and 11 α1BAR-KO 
mice with approximately equal numbers of male and female animals. The 2 mo old mice 
comprised Group 2 and included 13 WT, 22 α1AAR-, and 14 α1BAR-KO mice also with 
approximately equal numbers of male and female mice. Mice received pelleted food with 
5% fat (Teklad 22/5 Rodent Diet (W) 8640, Harlan, Indianapolis, IN) and water ad libitum, 
were maintained on a 12-hr light cycle (on at 0700 hrs), and provided veterinary care. All 
protocols conformed to the Guide for the Care and Use of Laboratory Animals and were 
approved by the Institutional Animal Care and Use Committee at the University of North 
Dakota. The transgenic mice were created as previously described and littermates were 
used as controls (Cavalli et al., 1997; Rokosh and Simpson, 2002). Group 1 α1AAR-KO mice 
were of the F7-8 generation and α1BAR-KO mice of the F9 generation. Group 2 α1AAR-KO 
mice were of the F3, F5, and F9 generation and α1BAR-KO mice the F5 and F11 generation. 
Seizure Incidence 
The incidence of seizures was noted anytime the mice were observed, mainly prior 
to and during behavioral testing. Seizure occurrence was identified as “seizure” or “no 
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seizure” (McKhann et al., 2003). Seizures were not classified by stage. However, observation 
indicated that seizures included Stages 1-3, immobility, rigidity, and head bobbing. No notes 
indicate that seizures progressed to Stages 4-6, intermittent or continuous rearing and 
falling or whole body convulsions. 
Behavioral Testing 
Testing for Group 1 started at 160 d of age (Figure 15A). Group 2 testing began when 
mice were approximately 90 d of age (Figure 15B). Testing was completed between 1200 
and 1700 hrs except open field which was performed between 0730 and 1200 hrs. 
Following locomotor and mood testing, Group 1 was involved in a learning and memory 
study not reported here. Mice were acclimated to individual cages in the testing room 
without food and water for 1 hr prior to testing, except for zero maze and open field when 
acclimation was 30 min. Lighting was adjusted using a LX1010B digital lux meter 
(Amazon.com, Seattle, WA). The tests and analysis were performed blind to genotype. 
Open field test. The open field test was used to assess basal locomotor activity in 
Group 1 mice. Mice were placed in a 43.2 x 43.2 cm open field equipped with infrared 
beams every 2.54 cm above the floor of the field. Mice were allowed to roam freely for 20 
min while activity was recorded. The data were analyzed using Activity Monitor 6.0 and 
Activity MDBtoExcel for distance traveled each min, total distance traveled, and time spent 
in the center zone (MedAssociates, St. Albans City, VT). The center zone was defined as a 
center square of 29.12 x 29.12 cm. Light was ambient room lighting at approximately 250 
lux. 
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Figure 15. Behavioral timelines. A) Group 1 mice were tested for anxiety in the elevated zero maze, 
underwent a general health assessment, and were tested in the open field for locomotion (distance 
traveled) and anxiety (time spent in the center of the field). B) Group 2 mice were tested for anxiety 
in the elevated zero maze, marble burying test, and light dark exploration and for depression in the 
tail suspension test. 
 
Zero maze. The zero maze was used to test anxiety (Stoelting, Wood Dale, IL). The 
maze consisted of an elevated circular walkway with a diameter of 59.7 cm and a lane width 
of 5 cm. Due to previous trials where mice jumped off the maze to the floor; the maze was 
placed on a table 72.4 cm in height. The maze was divided into 4 quadrants: two open and 
two with 15.4 cm high walls. Light was held constant across the maze at 40 lux to mimic a 
mouse’s ethological environment. Mice were placed on the maze facing a closed area and 
were allowed to explore for 10 min. The time spent in each area, open or closed, was 
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determined when all four paws entered. The tests were recorded from an overhanging 
camera and used to analyze the time spent in and entries into the open areas. 
Light Dark Exploration. Light dark exploration was used to test anxiety using a 
modified open field box (Stoelting, Wood Dale, IL). The 40 x 40 x 35 cm box was divided by 
an opaque plexiglass insert into a light side (40 x 26 x 35 cm) and dark side (40 x 14  x 35 cm) 
connected by a 7.5 x 7.5 cm opening. The dark side was kept at 0 lux by addition of an black 
opaque plexiglass lid. The light side was illuminated by overhead fluorescent lighting, 
approximately 220 lux within the box. Each mouse was placed in the light facing away from 
the opening to the dark section and allowed to explore for 10 min. A mouse was considered 
to have entered a side of the box when all four paws entered. The trials were digitally 
recorded and later analyzed for the latency to enter the dark side, time spent in the light 
side, and the number of entries into the light side.  
Marble burying test. The marble burying test was used to assess obsessive 
compulsive-type anxiety behavior. A 17 x 28 x 13 cm polycarbonate box held 10 cm of 
sawdust bedding with 20 marbles placed on top. Lighting was held constant at 40 lux within 
each box. Each mouse was placed in a box and allowed to explore for 30 min then removed. 
Marbles were considered buried if more than two-thirds covered with sawdust bedding. 
Tail suspension test. The tail suspension test was a 29.2 x 21.6 x 24.1 cm box made 
of 1.27 cm white melamine-coated particle board with a hook in center top of the box. A 
tape loop was placed on the tail of each mouse, which was then suspended on the hook for 
6 minutes. Tail climbing was a frequent occurrence, as is common in the C57BL/6 strain 
(Mayorga and Lucki, 2001). Mice that tail climbed longer than 72 s (20 percent of the time) 
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were excluded. A subset of mice were tested a second time using a 3.8 cm long, 1.27cm in 
diameter hard plastic tube placed between the base of the tail and the tape loop to 
discourage tail climbing (Can et al., 2012).  
Statistical Analysis 
Statistical analyses were performed using GraphPad Prism 5.04 (GraphPad Software, 
San Diego, CA). The Kolmogorov Smirnov test was used to assess normality and the 
Bartlett’s test was used to determine if variances were equal. ANOVAs were still used when 
a set of data were not normally distributed because ANOVA are robust for violations of 
normality and the equal variances assumption was met. When the variances differed, the 
Kruskal Wallis test was used with a Dunn’s post-hoc test. Outliers were detected and 
excluded using the Grubb’s test. Differences between groups were assessed with one-way 
ANOVA and a Tukey post-hoc test. Sex differences were detected using a two way ANOVA 
with genotype X sex and Bonferroni post-test for paired comparisons. The effect of the tail 
tube on tail climbing was determined using a Mann-Whitney test because the data were not 
normally distributed. 
Results 
Seizure Incidence 
α1AAR-KO mice have an increased incidence of seizures. CAM-α1BAR mice, with a 
mutation that keeps the receptor in its active conformation, have an age-related seizure 
disorder (Zuscik et al., 2000). Knock out the α1BAR protects against seizures (Pizzanelli et al., 
2009). Due to this, we did not expect nor observe seizures in the α1BAR-KO mice. Similarly, 
no seizures were observed in WT mice. Group 1 α1AAR-KO mice had a seizure incidence of 
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50 percent while Group 2 α1AAR-KO mice had an incidence of 13 percent (2 mice). Seizure 
incidence was roughly equal in male and female mice. Due to the high level of seizure 
incidence, all behavioral tests for Group 1 were analyzed to determine if prior seizure 
activity had an effect on the parameters of each test. If so, the results were analyzed again 
separating α1AAR-KO mice that did not have seizures and those that did. 
Open Field 
α1A or α1BAR knockout did not affect basal locomotion in Group 1 mice. Changes in 
basal locomotion make behavioral results challenging to interpret (Crawley and Paylor, 
1997). Therefore, we examined basal locomotion in the open field test in Group 1. We 
previously showed that activation of the α1AAR does not change basal locomotion but 
activation of the α1BAR increases the total number of beam breaks in the open field 
compared with WT mice (Doze et al., 2009). Knauber and Müller. found that α1BAR-KO mice 
traveled shorter distances (Knauber and Müller, 2000). In contrast, another study showed 
that α1BAR-KO mice traveled longer distances in the open field (Spreng et al., 2001). In the 
current study, there were no differences in total distance traveled in the open field 
between groups [F(2, 44) = 2.32, p = 0.10, Figure 16]. There was a main effect of sex in the 
total distance traveled [F(1, 41) = 7.421) = p = 0.009] where female α1AAR-KO and α1BAR-KO 
animals traveled less distance than female WT mice (p < 0.05). There was also an interaction 
of sex [F(2, 41) = 3.834, p = 0.03]. There were no differences between α1AAR-KO mice that 
had seizures vs α1AAR-KO mice without seizures [t(20) = 0.03, p = 0.98]. These results show 
that in male mice locomotion was not affected by the lack of the receptor subtypes or by 
seizure incidence. Female α1AAR-KO and α1BAR-KO have decreased locomotion.  
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Figure 16. Open field test in Group 1. There was no difference between WT, α1AAR-KO, and α1BAR-
KO in the total distance traveled. Shown as A) distance traveled over time and B) total distance 
traveled (p = 0.10).  
 
In Group 1, knockout of either subtype did not affect anxiety in the open field; 
α1AAR-KO mice had higher levels of anxiety in the elevated zero maze after accounting for 
seizure activity; α1BAR-KO did not affect anxiety. α1AAR activation decreases anxiety 
behavior while α1BAR activation has no effect on anxiety (Doze et al., 2009). To further study  
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Figure 17. Anxiety in Group 1, Open field time in center. There were no main effects of A) time (p = 
0.35) or B) percentage of time (p = 0.35) spent in the center of the open field, a measure of anxiety.  
 
the effects of α1AR subtype function on anxiety behavior, the open field data from Group 1 
was analyzed for the time spent in the center zone. In addition, Group 1 mice were tested in 
the elevated zero maze. We hypothesized that α1AAR-KO would result in more anxiety-like 
behavior while α1BAR-KO would not affect anxiety. 
Open Field Time Spent in the Center Zone 
Time spent in the center of an open field is often used as a preliminary anxiety test 
(Crawley and Paylor, 1997). In Group 1 mice, there were no significant differences in the 
time spent in the center of the field [F(2, 44) = 1.07, p = 0.35] or in the percentage of time 
spent in the center [F(2, 44) = 1.04, p = 0.35] (Figure 17A and 17B). There was no effect of 
seizure incidence in the α1AAR-KO mice on the time spent in the center of the field [t(20) = 
0.066, p = 0.94] or the percentage of time spent in the center [t(20) = 0.04, p = 0.96]. There 
was no effect of sex in the time spent in the center of the open field [F(1, 41) = 0.43, p = 
0.51]. There was an interaction between sex and genotype [F(2, 41) = 5.36, p = 0.008] such 
that female α1BAR-KO mice spent less time in the center than female WT mice (p< 0.05).  
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Zero Maze, Group 1 
There were no significant differences in the time spent in the open areas of the 
elevated zero maze when seizure activity was not accounted for [F(2, 46) = 2.363, p = 0.10] 
(Figure 18A). There was a main effect of genotype in the number of entries made into the 
open areas [F(2, 45) = 9.58, p = 0.003] (Figure 18B). A Tukey post-hoc test showed that 
α1AAR-KO mice made fewer entries into the open areas compared with both WT (p < 0.001) 
and α1BAR-KO mice (p < 0.05). There was no effect of sex in the time spent in the open areas 
[F(1, 43) = 0.49, p = 0.48] or entries [F(1, 43) = 0.66, p = 0.41]. 
Reanalysis of the data after separating α1AAR-KO mice that had seizures and mice 
that did not, revealed a main effect in the time spent in the open areas [F(3, 35) = 4.746, p = 
0.0058] and confirmed the main effect on the number of entries into the open areas [F(3, 
35) = 5.343, p = 0.0031] (Figures 18C and 18D). Post-hoc testing showed that α1AAR-KO mice 
that did not have seizures spent less time in the open areas when compared with both WT 
(p < 0.01) and α1BAR-KO mice (p < 0.05). α1AAR-KO mice that did not have seizures also 
made fewer entries into the open areas when compared with both WT (p < 0.001) and 
α1BAR-KO mice (p < 0.01). These results show that Group 1 α1AAR-KO mice that did not have 
seizures have a higher level of anxiety in the elevated zero maze while α1AAR-KO mice that 
did have seizures and α1BAR-KO mice have anxiety levels similar to WT animals. 
Zero Maze, Group 2 
In Group 2, α1AAR-KO Mice had anxiety levels similar to WT; Lack of α1BAR subtype 
activity did not reliably affect anxiety behavior. For additional study on the effect of α1AR 
subtype function on anxiety behavior, Group 2 mice were also assessed in the elevated zero 
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Figure 18: Anxiety in Group 1, Zero maze. In the zero maze: there was no effect of genotype for the 
A) time spent in the open areas. There was a main effect of genotype in the B) number of entries 
into the open arms. A Tukey post-hoc test showed that the α1AAR-KO mice made fewer entries into 
the open arms when compared with WT (p < 0.001) and α1BAR-KO mice (p < 0.01). When mice with a 
history of seizures were separated from those that did not, a main effect was found for the C) time 
spent in the open areas. Post-hoc analysis showed that α1AAR-KO mice that did not have seizures 
spent less time in the open area when compared with WT (p < 0.01), α1AAR-KO (seizure) (p < 0.05), 
and α1BAR-KO mice (p < 0.05). There was also a main effect on the number of D) entries to the open 
areas of the zero maze. A Tukey post-hoc test revealed that α1AAR-KO mice that did not have 
seizures made significantly fewer entries into the open areas when compared with WT (p < 0.01) 
and α1BAR-KO mice (p < 0.05). * p < 0.05, ** p < 0.01, *** p < 0.0001 
 
maze as well as the light dark exploration and marble burying tests. The low number of 
Group 2 α1AAR-KO mice that had seizures (n = 2) precluded testing for the effect of seizure 
incidence in this group. Our hypothesis was the same as for Group 1 mice: that α1AAR-KO 
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would result in a higher level of anxiety-like behavior while α1BAR-KO would not affect 
anxiety. 
In the zero maze, there were no significant differences in the amount of time spent 
in the open areas [F(2, 40) = 2.81, p = 0.07] (Figure 19A). There was a statistically significant 
difference between groups in the number of entries into the open areas of the zero maze 
[F(2, 40) = 4.32, p = 0.02] (Figure 19B). Post-hoc testing showed that α1BAR-KO mice made 
fewer entries into the open areas compared with WT mice (p < 0.05). There were no sex 
differences in either the time spent in [F(1, 36) = 3.25, p = 0.07] or entries into the open 
areas [F(1, 37) = 0.44, p = 0.51]. The results show a possibility that α1BAR-KO mice have a 
higher level of anxiety than WT mice based on the reduced entries into the open areas of 
the elevated zero maze. However, this was not confirmed in the time spent in the open 
areas of the maze.  
Light Dark Exploration 
In an earlier study, we saw no difference in anxiety behavior in the light dark 
exploration after transgenic or pharmacological activation of the α1AAR or α1BAR (Doze et 
al., 2009). In a more recent study, α1AAR activation significantly increased the time spent in 
the light side of the light dark exploration test (Doze et al., 2011). We hypothesized that KO 
of the α1AAR would lead to a higher level of anxiety in the light dark exploration test. 
In the current study, there were no statistically significant differences in the light 
dark exploration for the time spent in the light side [F(2, 39) = 1.34, p = 0.27] (Figure 19C), 
entries to the light side [F(2, 40) = 1.21, p =0.30] (Figure 19D), or latency to enter the dark 
side [F(2, 39) = 1.04, p =0.36] (Figure 19E). There was a main effect of sex in the time spent  
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Figure 19. Anxiety in Group 2: Zero maze, light dark exploration, and marble burying test. Lack of 
α1AAR or α1BAR function did not reliably affect anxiety behavior. In the zero maze, there were no 
significant differences between WT, α1AAR-KO, or α1BAR-KO for the A) time spent in the open areas 
(p = 0.054). There was a main effect of genotype in the B) entries made into the open areas of the 
zero maze (p = 0.015). Tukey’s post-hoc test revealed that α1BAR-KO mice made fewer entries into 
the open areas when compared with WT and α1AAR-KO mice (p < 0.05 for each comparison). In the 
light dark exploration, there was no effect of genotype in the C) time spent in the light side (p = 
0.272), D) entries to the light side (p = 0.308), or E) latency to enter the dark side of the maze (p = 
0.362). In the marble burying test, there was a significant difference in the number of marbles 
buried between groups (p  = 0.005). A Dunn’s post-hoc test showed that α1BAR-KO mice buried 
significantly more marbles than α1AAR-KO mice but not WT mice. * p < 0.05, ** p < 0.01 
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in the light side [F(1, 36) = 7.12, p = 0.011]; however, no post-hoc differences were seen. 
The results suggest there are no differences in anxiety between genotypes in light dark 
exploration.  
Marble Burying Test 
We have previously shown that transgenic or pharmacological α1AAR activation 
decreases the number of marbles buried in the marble burying test, showing a lower level 
of anxiety than in WT or control mice (Doze et al., 2009). Activation of the α1BAR did not 
have an effect on the number of marbles buried. Therefore, we hypothesized that KO of the 
α1AAR would increase anxiety behavior in the marble burying test compared with WT mice 
but α1BAR-KO would have no effect.  
There was a statistically significant difference in the number of marbles buried [χ2(3) 
= 10.54, p = 0.005] (Figure 19F). A Dunn’s post-hoc test showed that α1BAR-KO mice buried 
more marbles than α1AAR-KO mice (p < 0.01) but not more than WT mice (p > 0.05). There 
was no main effect of sex in the marble burying test [F(1, 37) = 0.75, p = 0.39]. The results of 
the marble burying test suggest there are no differences in obsessive-compulsive type 
anxiety between the α1BAR-KO and WT but that α1BAR-KO mice have a higher level of 
anxiety compared with α1AAR-KO mice.  
Tail Suspension Test 
Loss of α1BAR function decreased immobility when tail climbing was reduced. 
Activation of the α1AAR, either using transgenic mice or pharmacological means, previously 
showed a robust decrease in depression-like behavior in the tail suspension test which was 
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blocked by prazosin, an α1AAR antagonist (Doze et al., 2009, 2011). Transgenic α1BAR 
activation led to a higher level depression-like behavior in the tail suspension test.  
In the current study, there were no significant differences in the time spent 
immobile in the tail suspension test [F(2, 30) = 0.50, p = 0.61] (Figure 20A). However, two 
mice per group had to be excluded for tail climbing greater than 20 percent of the time. 
Other mice spent time tail climbing that they otherwise may have spent immobile; 
however, tail climbing in these mice was not present for greater than 20 percent of test 
time. In order to detect potential differences, a hard plastic tail tube was used to prevent 
mice from climbing their tail (Can et al., 2012). To assess the effect of the plastic tube as a 
barrier to tail climbing, all data were pooled. The reduction in tail climbing was statistically 
significant (U = 236.5, p < 0.0001) (Figure 20B). Under these conditions, there was a 
difference in the time spent immobile between groups [F(2, 28) = 10.80, p = 0.0003]. A 
Tukey post-hoc test showed that α1BAR-KO mice spent less time immobile than both WT (p 
<0.001) and α1AAR-KO mice (p < 0.01) (Figure 20C). There were no sex differences in the no-
tail-tube [F(1, 27) = 0.60, p = 0.44] or tail tube version of the tail suspension test [F(1, 25) = 
x2.01, p = 0.16]. These results suggest that α1BAR-KO results in lower levels of depression-
like behavior. 
Discussion 
Locomotion was not different between groups overall, similar to another study using 
only male α1BAR-KO mice (Spreng et al., 2001). However, another report using male α1BAR- 
KO mice showed a reduction in open field locomotion. In the current study, both α1A- and 
α1BAR-KO female mice traveled less distance in the open field but an interaction of
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Figure 20. Depression-like behavior in Group 2, Tail suspension test. In the tail suspension test, there 
was no effect of genotype on A) the time spent immobile when mice were tested without an 
obstruction to tail climbing (p = 0.610). Using a hard plastic tube to impede tail climbing there was B) 
a significant reduction in the amount of time spent tail climbing (p < 0.0001). Retesting with a tail 
tube revealed C) a main effect of genotype on the time spent immobile (p = 0.0003). A Tukey post-
hoc test showed that α1BAR-KO mice spent less time immobile when compared with both WT (p < 
0.001) and α1AAR-KO (p < 0.01) mice. * p < 0.05, ** p < 0.01, *** p < 0.0001 
 
genotype and sex makes the result difficult to interpret. Locomotion was not likely a 
confounding factor as no sex differences were found in any behavioral tests. This is the first 
study to examine anxiety and depression-like behavior after KO of the α1AAR- and α1BAR 
(Spreng et al., 2001). Our results show that the α1AAR subtypes are involved in anxiety 
behavior in 4-month old mice lacking the α1AAR only in those mice that did not have 
observed seizures. Conversely, mice lacking the α1BAR receptor subtype exhibited less 
depression-like behavior and unclear effects on anxiety.  
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Therapeutics for depression often alleviate symptoms of both depression and 
anxiety, which is a common comorbid finding (Kessler et al., 2003). Previous research has 
shown conflicting results for the α1AR’s role in depression and anxiety, likely due to the lack 
of highly selective agonists and antagonists able to cross the blood brain barrier (Cunha et 
al., 2013; Danysz et al., 1986; Borsini et al., 1984; Pulvirenti and Samanin, 1986). The current 
study furthers our understanding of α1AR function in the central nervous system and the 
behaviors elicited. Early behavioral work from our lab showed that activation of the α1AAR 
led to a lower level of depression and marble burying but not anxiety behavior in the 
elevated plus maze or light dark exploration (Doze et al., 2009, Figure 21). In a subsequent 
study, we utilized littermate controls and lowered the lighting for the elevated zero maze to 
better mimic the natural mouse habitat. Our findings were that α1AAR activation also led to 
a lower level of anxiety in the elevated zero maze and light dark exploration tests (Doze et 
al., 2011). In corroboration with these studies, in the current investigation α1BAR-KO mice 
had a lower level of depression compared with WT demonstrating a role for this subtype in 
depression. Both transgenic and pharmacological activation studies suggested a role for the 
α1AAR in depression. Surprisingly, α1AAR-KO mice did not show more depression-like 
behavior even after removing the opportunity for tail climbing. The role of the α1AR 
subtypes in depression and anxiety appears to be more complex than anticipated and 
additional factors are likely involved.  
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Figure 21. Overview of activation and KO of α1AR subtype effects on behavior. Previous studies 
showed that transgenic activation of the α1AAR reduces depression and anxiety-like behaviors and 
increases the seizure threshold, showing anti-epileptic properties (Doze et al., 2009, 2011, Doze, 
Jurgens, Nelson, and Goldenstein, unpublished data). Pharmacological activation of the α1AAR also 
reduced depression levels (Doze et al., 2009). Activation of the α1BAR increased depression-like 
behavior but had no effect on anxiety. In the current study, α1AAR-KO did not affect depression-like 
behavior but had a potentially age-related effect on seizure activity and anxiety. Older mice, Group 
1, mice had a higher occurrence of seizures and mice in Group 1 that did not have seizures had 
increased anxiety. The younger mice, Group 2, had a lower occurrence of seizures and no change in 
anxiety levels. α1BAR-KO mice had lower depression-like behavior but no change in anxiety in Group 
1 mice and unclear results on anxiety in Group 2 mice. 
 
There are many potential explanations for the unclear results; one is that the 
receptor subtypes require heterodimerization for some behavioral effects. GPCRs are 
known to heterodimerize in vitro and in vivo, with some heterodimers required for or 
changing downstream effects of the receptors alone. There is also in vivo evidence that 
GPCR heterodimerization is involved in neuropsychiatric disorders. The D1-D2 heterodimer 
is increased in human post-mortem brain and blocking formation of the heterodimer in rats 
led to a reduction in immobility in the forced swim test (Pei et al., 2010).  The α1AR subtypes 
can form heterodimers in vitro, which could potentially confer functional changes (Uberti et 
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al., 2003). Heterodimers of the α1AAR and α1BAR subtypes increase binding site density and 
protein expression of the α1AAR with no change in the α1BAR (Uberti et al., 2003). Increased 
density and protein expression suggest sensitization to the ligand and could increase 
downstream activity in vivo. The ratio of receptor subtypes may also be important.  
In the CAM-α1BAR mice, the α1AAR is still present though at lower levels and activity 
than the α1BAR, likely even after accounting for increased α1AAR expression due to potential 
heterodimerization. The increased ratio of α1BARs and their constitutive activity appears 
sufficient to induce depression (Doze et al., 2009). In the current study, α1BAR-KO reduces 
depression-like behavior but it is unknown if the lack of α1BAR signaling is sufficient for this 
reduction or if the still present α1AAR is necessary. α1AAR-KO mice show no change in 
depressive activity, which suggests that lack of α1AAR activity alone is not sufficient to 
induce depression. It is interesting to speculate that heterodimerization to increase α1AAR 
density and expression may be needed. In CAM-α1AAR mice, with both constitutive α1AAR 
activity and increased surface expression of the α1AAR due to hetero-dimerization, 
depression is reduced. But it is also reduced when the endogenous α1AAR is activated via an 
α1AAR agonist, cirazoline, and returns to control levels when CAM-α1AAR mice are treated 
with an α1AR antagonist, prazosin (Doze et al., 2009).  
To add to the complexity, the α1AR subtypes are not expressed at the same levels in 
all brain areas and there is evidence that the expression level affects whether receptors 
homo- or heterodimerize. Heterodimerization can also occur between different classes of 
receptors, such as with the D2 and SST receptors (Molchan et al., 1991). Clearly, more work 
is needed to clarify the role of each receptor subtype in depression behavior. Using α1AR 
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selective agonists or antagonists in CAM-α1BAR, α1AAR-KO, and α1BAR-KO mice would be a 
logical next step. Future research in this area should also explore α1AAR activation and 
α1BAR blocking in a mouse model of depression. Do these actions change only basal levels of 
depression, prevent depression, or relieve depression once it has begun? 
The remaining question about anxiety behavior is also complex. There was no clear 
outcome for knockout of either subtype in other measures of anxiety. Possibly, the 
expression of both subtypes is necessary for changes in anxiety. Future work could utilize 
double-KOs of the α1AAR and α1BAR subtypes and combinations of single gene knockouts 
and α1AR ligands.  
In summary, we showed that α1BAR-KO reduced depression-like behavior in the tail 
suspension test while α1AAR-KO affected anxiety in Group 1 animals that did not have 
seizures. These results provide evidence for a negative role of the α1BAR in depression and 
confirms a positive role for the α1AAR, which could be taken advantage of when designing 
therapeutics.  
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CHAPTER 4 
TREATMENT WITH CIRAZOLINE, AN ALPHA1AAR AGONIST, DOES NOT INFLUENCE FINAL 
CELL FATE IN THE ADULT MOUSE DENTATE GYRUS DURING ADULT NEUROGENESIS 
 
Abstract 
Adrenergic receptors (ARs), α1, α2, and β bind to the endogenous ligand 
norepinephrine. Each family of AR has three subtypes and the present study examined the 
α1AAR subtype’s role in adult neurogenesis. Adult neurogenesis occurs in two areas of the 
adult brain: the subventricular zone (SVZ) of the lateral ventricles and the subgranular zone 
(SGZ) of the dentate gyrus. α1AAR activation, via transgenic manipulation using a 
constitutively active mutant form of the receptor (CAM-α1AAR mice), increases proliferation 
of neural progenitor cells in both the SVZ and SGZ. In vitro work using adult-derived 
neurospheres from the SVZ of wild type and CAM-α1AAR animals suggested a role for these 
receptors in the differentiation stage of adult neurogenesis as well. In the present study, we 
treated C57BL/6 mice with the α1AAR agonist cirazoline for 8 wks and injected the S phase 
marker BrdU after 4 wks of treatment. We then performed double-labeling 
immunohistochemistry to examine the fate of the newly created cells at the 4 wk timepoint. 
We found that cirazoline treatment did not change the number or percent of cells that 
became NeuN+ mature neurons or GFAP+ mature astrocytes. There was a large effect size, 
but no statistical significance, suggesting a decrease in the number of DCX+ immature  
 
69 
 
neurons in the cirazoline treated group. The results suggest that the role of the α1AARs is 
complex and may be related only to the early stages of proliferation and differentiation. 
Introduction 
The catecholamine neurotransmitter norepinephrine signals through the α1-, α2-, 
and β adrenergic receptors (ARs). Each type of AR has three subtypes and the present study 
examined the role of the α1AAR subtype in adult neurogenesis. Adult neurogenesis is the 
process whereby new brain cells are generated in the adult brain (Figure 22). It occurs in 
two discrete areas, the subgranular zone (SGZ) of the hippocampal dentate gyrus and the 
subventricular zone (SVZ) of the lateral ventricles. The process includes several steps: 
proliferation, migration/ differentiation, and survival/ integration. It is mediated by growth 
factors, synaptic input, and neurotransmitters among others.  
The role of norepinephrine, and the α1AR subtypes, in the process of adult 
neurogenesis is not well understood. Xenopus laevis embryos and cell culture studies 
suggest a role for norepinephrine and the αARs in differentiation. For example, 
norepinephrine increases the number of embryonic cells that differentiate into neurons via 
α1ARs (Rowe et al., 1993; Messenger et al., 1999). However, not all regulators of embryonic 
neurogenesis are involved in adult neurogenesis. In adult mice, we previously showed that 
α1AAR activation, via transgenic or pharmacological methods, increases proliferation in the 
SGZ and the SVZ (Gupta et al., 2009). Our work with adult neurospheres cultured from 
mouse lateral ventricles shows that α1AAR stimulation affects differentiation and survival of 
new brain cells. 
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Figure 22. Adult neurogenic process. Proliferation: A) Neural stem cell (T1) dividing symmetrically or 
asymmetrically, B) Neural progenitor cell (T2) dividing symmetrically or asymmetrically, Migration 
and Differentiation: C) differentiating cells migrating into the granule cell layer, and Integration/ 
survival: D) integrating into the local circuitry. Adapted from Suh et al., 2009. 
 
In neonatal neurospheres derived from normal mice or transgenic mice that express 
a constitutively active mutant form of the α1AAR (CAM-α1AAR mice), stimulation with 
phenylephrine, an α1AR agonist, increases differentiation and migration and promotes 
survival of new cells (Gupta et al., 2009). In α1AAR-knockout mouse-derived neurospheres, 
the cells revert to or maintain an undifferentiated state, as assessed by an increase in 
nestin RNA expression and lack of changes in differentiation-related transcription factors. 
α1AAR signaling also promotes the survival of cultured neural progenitor cells by reducing 
stress-induced apoptosis (Ohashi et al., 2007). In vivo, only 60 percent of adult-generated 
cells in the SGZ survive more than two weeks (Kempermann and Gage, 2002). Those that 
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do survive are mostly of the neuronal phenotype and survive for at least eleven months 
(Kempermann et al., 2003).   
Approximately 50-60 percent of the new cells in the SGZ are neurons (Reviewed in 
Abrous et al., 2005; Steiner et al., 2004). Approximately 10 percent are astrocytes and 25 
percent of new cells are of an unknown phenotype. Astrocytes are important in the process 
of adult neurogenesis, releasing paracrine factors and balancing inflammatory mediators 
(Ashton et al., 2012; Lie et al., 2005). Astrocytes also promote the differentiation step of 
adult neurogenesis (Song et al., 2002; Oh et al., 2010). We previously showed that 
neurospheres derived from adult mouse SVZ and treated with phenylephrine increases glial 
markers (Gupta et al., 2009).  
In the current study, we hypothesized that α1AAR activation, via the selective 
agonist cirazoline, would promote survival of adult-born cells in the SGZ. Based on our 
adult-derived neurosphere evidence, we also hypothesized that a higher number of 
astrocytes would be generated when compared with wild type. 
Methods 
Animals 
Animals were C57BL/6 wild type (WT) mice kindly donated by Dr. Colin Combs and 
Dr. Kendra Puig at the University of North Dakota. All animals were provided veterinary care 
at the University of North Dakota, an American Association for Laboratory Animal Science 
accredited institution. The Institutional Animal Care and Use Committee approved all 
protocols. Eight mice/ sex/ group were 10 wks old at the start of the study. Standard 
acidified water, provided by the Center for Biomedical Research at UND was provided in 
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250 ml glass bottles with intake monitored weekly. Harlan Teklad chow with 5 percent fat 
was provided ad libitum and intake monitored on a weekly basis.  
Drug Treatment and BrdU Administration 
Cirazoline hydrochloride was diluted to 40 µM in water provided by the Center for 
Biomedical Research animal facility (Tocris Bioscience, Minneapolis, MN). Control mice 
received the same water without drug. Treatment began when mice were 10 wks of age 
and continued until cardiac perfusion at 18 wks of age (Figure 23). After 4 wks of cirazoline 
treatment, BrdU was injected to label S phase dividing cells. BrdU was diluted to 10 mg/ml 
in saline then warmed and mixed by vortex for several min. BrdU was administered IP at 50 
mg/kg twice per day, 12 hrs apart, for 5 d.  
Tissue Preparation 
Eight weeks after the start of cirazoline or control water administration, mice were 
anesthetized with a terminal dose of pentobarbital (150 mg/ml) and perfused. Using gravity 
perfusion equipment, 10 ml of ice-cold heparinized saline (0.02 mg/ml in 0.9 percent saline) 
was infused through the left ventricle using a 22G short bevel needle. This was followed by 
30 ml of 4 percent paraformaldehyde (Fisher Scientific, Hanover Park, IL). Brains were 
removed and post-fixed for 2 d in 4 percent paraformaldehyde then transferred to 0.1 M 
phosphate buffered saline with 0.01 percent sodium azide (Fisher Scientific, Hanover Park, 
IL). Brains embedded in 3 percent agarose were sectioned at 40 μm on a vibrating 
microtome (MICROM, Thermoscientific, Watham, MA) in an ice cold PBS bath. Sections 
were collected and placed in PBS, ethylene glycol, and glycerol-containing cryoprotectant 
solution in 96 well plates. Approximately 60-70 sections per brain were kept with one
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Figure 23. Treatment timeline. Mice were 10 wks old at the start of treatment. Cirazoline treatment 
lasted for 8 wks. BrdU was injected IP 2x/ d for 5 days after 4 wks of cirazoline treatment. 
 
section per well and one brain per plate. Sections in well plates were stored at -20 C until 
used for immunohistochemistry. 
Immunohistochemistry 
Brains used for immunohistochemistry were pseudorandomly chosen from each 
group. For each labeling experiment, a 1 in 6 series of sections was used, with the starting 
section determined by the roll of a 6-sided die. Free-floating labeling took place in 12 well 
plates, each well containing the sections from one mouse. Negative controls, for specificity 
of the secondary antibody, included a well without primary antibody and one well 
containing primary antibody host IgG at the same concentration as the antibody (Jackson 
Immunoresearch, West Grove, PA). Positive controls for BrdU and DCX were from a 4 wk old 
mouse injected at a 2 hr BrdU timepoint. Positive controls for astrocytes (GFAP) were cells 
in the hilus and molecular layer of the dentate gyrus. All sections were double-labeled with 
Rat x BrdU and one of the following primary antibodies: Mouse x NeuN, Goat x DCX, or 
Mouse x GFAP (Table 2). AlexaFluor (AF) secondary antibodies included Goat x Rat AF488, 
Goat x Mouse AF568, and Donkey x Goat AF568. Either DAPI or TOPRO-3 was used as a 
counterstain.  
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Mature neurons: BrdU + NeuN. Sections were washed with 1X (0.1 M) phosphate 
buffered saline, incubated with 2N HCl for 30 min at 37 C, then rinsed with 0.1 M borate 
buffer. Sections labeled for Ms x NeuN were blocked using a Ms x Ms blocking buffer 
(Scytek, Cat. #MTM008, Logan, UT). NeuN sections were also blocked with 10 percent 
bovine serum albumin diluted in 5 percent normal serum from the secondary antibody host 
species in 1X PBS. Primary antibody incubation lasted 24 hr. Sections were washed then 
incubated with corresponding secondary antibodies for 2 hr. Sections were protected from 
light during secondary antibody incubation and thereafter. After the secondary antibody, 
the sections were washed, and incubated with 10 mM CuSO4 solution in a 50 mM 
Ch3COONH4 buffer for  1 hr. After rinsing, sections were counterstained with DAPI at 1 
μg/ml and mounted on SuperFrost Plus slides in a 0.1M phosphate buffer, coverslipped with 
a PVA/ DABCO mounting medium (cite Peterson’s chapter here). Slides were left to dry 
overnight and then stored at 4°C until imaging. 
Immature neurons and mature astrocytes: BrdU + DCX and BrdU + GFAP. Sections 
were washed in 10X Tris buffered saline, incubated in 10N HCl at 37C for 10 min, then 
rinsed in 0.1 M borate buffer. Sections were blocked with Ms x Ms blocking buffer, if 
needed, then blocked with 5 percent normal serum of the secondary antibody host species 
diluted in 10X TBS. Primary antibody incubation was 72 hr (GFAP and DCX) at 4°C. Sections 
were rinsed with blocking buffer containing 5 percent normal serum two times, 1 hr each. 
While protected from light, sections were incubated with secondary antibodies for 2 hr then 
rinsed and incubated with CuSO4/ Ch3COONH4 solution, mounted, cover-slipped, and stored 
as above until counting. 
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Imaging and Cell Counting 
BrdU + NeuN labeled samples were imaged using a 5X51WI Olympus DSU 
microscope at the Center for Stem Cell and Regenerative Medicine Confocal Stereology 
Research Laboratory at Rosalind Franklin University (Olympus Scientific Solutions, Waltham, 
MA). StereoInvestigator 11.0 and the Virtual Tissue feature were used to set up the 
contours and imaging continued overnight (MBF Bioscience, Williston, VT). Image files were 
provided to the University of North Dakota via Dropbox (Dropbox, Inc., San Francisco, CA). 
One hemisphere was counted. Cells labeled with BrdU and double-labeled with NeuN were 
counted exhaustively in the 1 in 6 series of sections using StereoInvestigator 10.0, excluding 
any cells where the top of the cell was out of focus. The total number of BrdU+ and 
BrdU+NeuN+ cells were determined by multiplying the number of counted cells by 2 (for the 
other hemisphere) and then by 6 for the 1 in 6 series. The percentage of double-labeled 
cells was determined using the total counts of BrdU+ and BrdU+NeuN+ cells. All other images 
were taken on an Olympus Fluoview 1000 at the University of North Dakota.   
BrdU + DCX and BrdU + GFAP cell counting. Double-labeling experiments for BrdU 
and either DCX or GFAP were counted on an Olympus Fluoview 300 microscope using 
epifluorescence (Olympus Scientific Solutions, Waltham, MA). BrdU and double-labeled cells 
were counted exhaustively in the 1 in 6 series of sections. DCX only cells were counted in a 
1 in 12 series of the same samples. Missing sections were accounted for by adding the 
average number of cells in a brain to the final counts.  
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Statistics 
Data were analyzed using GraphPad Prism 5.04. Kolmogorov-Smirnov test was used 
to assess normality and the Bartlett’s test for equal variances. Unpaired t-tests were used 
for normally distributed data when the means were equal. If the assumption of normality 
was not met, a non-parametric Mann-Whitney test was used. Data with unequal variances 
was assessed using a t-test with Welch’s correction. Effect sizes were analyzed using 
Cohen’s d test.  
Results 
Body Weight and Water Intake 
Cirazoline decreases food intake, without a change in water intake, when given 
acutely (Wellman and Davies, 1992; Davies and Wellman, 1992). Caloric restriction can 
affect the proliferation stage of neurogenesis. Therefore, we analyzed body weight and 
water intake to ensure cirazoline did not induce caloric restriction. There were no statistical 
differences in body weight between control and cirazoline-treated mice [F(1, 287) = 0.10, p 
= 0.74]. There was a difference in weight over time but that was expected based on the age 
of the mice [F(7, 287) = 105.6, p < 0.0001]. That there was no difference in body weight 
between groups suggests there was no difference in food intake. In a separate study, there 
was no difference in food intake between control and cirazoline-treated mice over 20 wks 
of treatment (Collette and Doze, unpublished).  
A two-way ANOVA showed a difference in water intake between groups [F(1, 273) = 
12.84, p < 0.0009] and over time [F(7, 273) = 13.97, p < 0.0001]. Post-hoc testing revealed 
that cirazoline-treated mice drank less water on Weeks 2-8 (Figure 24). The estimated daily 
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dose for cirazoline, based on water intake, was 0.4 mg/day. There was a main effect of 
treatment on the amount of water drank when analyzed for sex differences [F(1, 37) = 1.44, 
p = 0.03]. There was not a main effect of sex [F(1, 37) = 1.44, p = 0.23] and there was an 
interaction between treatment and sex [F(1, 37) = 19.03, p < 0.0001]. The interaction makes 
the results difficult to interpret. However, a Bonferroni post-hoc test showed that 
cirazoline-treated female mice drank less water than female control mice (p < 0.0001). 
Survival 
The total number of BrdU+ cells surviving after four weeks was not significantly 
different between groups [U(70, 100) = 22.50, p = 0.22, Figure 25A]. This suggests that 
α1AAR activation does not affect cell survival.  
Differentiation 
Immature neurons. The total number of DCX+ cells was not significantly different 
between control and cirazoline-treated groups [t(5) = 2.11, p = 0.08, Figure 25B]. However, 
the effect size was very large (Cohen’s d = 1.22). The variability in the control group was 
much higher (95% confidence intervals: control 14,065 - 46,701 vs cirazoline: 10,731 - 
21,887). The high variability could likely be resolved with a higher number of animals, 
clarifying the results. 
BrdU+DCX+ cells, adult-created cells in the immature neuron stage four weeks post-
BrdU, was not statistically different [t(5) = 1.94, p = 0.10, Figure 25C]. Again, the effect size 
was large (Cohen’s d = 1.12) and confidence interval was larger in the control group (301 - 
730) than the treated group (304 - 396). The percentage of double-labeled cells was also not 
different [U(44, 34) = 13.00, p = 0.46, Figure 25D]. 
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Figure 24. Water intake and body weight. A) Cirazoline-treated mice drank significantly less water 
than control mice after Week 1 but B) body weight did not differ between the groups (p = 0.74). *p < 
0.05, **p < 0.01 
 
Mature neurons. There was no difference between control and cirazoline-treated 
mice in the total number [U(43.5, 34.5) = 13.50, p = 0.52, Figure 26A] or percent [U(47.5, 
30.5) = 9.50, p = 0.19, Figure 26B] of BrdU+NeuN+ mature neurons after 4 wk. The 
percentage of new cells differentiating into neurons was similar to previous research 
(Steiner et al., 2004; Kempermann and Gage, 2002). These results suggest that cirazoline 
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Figure 25. Immature neurons. A) There was no difference in the total number of BrdU+ cells (p = 
0.22). B) There was also no statistically significant difference between groups in the total number of 
DCX+ cells (p = 0.08). However, C) there was a large effect size, but no significant difference in the 
number of double-labeled BrdU+DCX+ cells in the cirazoline group (p = 0.04) and D) the percent of 
BrdU+DCX+ cells was not different (0.46). Representative images are shown for E) control and F) 
cirazoline-treated animals. Arrowheads show double-labeled cells, arrows show single-labeled BrdU 
cells.  
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Figure 26. Mature neurons. There was no difference between control and cirazoline-treated mice in 
the A) total number (p = 0.52) or B) percent (p = 0.19) of BrdU+NeuN+ cells after 4 wk. 
Representative images are shown for C) control and D) cirazoline groups. Arrowhead shows double-
labeled cells, arrow shows single-labeled BrdU cells. 
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treatment does not change the number or percent of new cells that differentiate into 
mature neurons. 
Astrocytes 
Chromogen. There was no statistical difference between control and cirazoline-
treated groups in the total number of BrdU+GFAP+ cells 4 wks post-BrdU [U(54, 99) = 33.00, 
p = 0.95, Figure 27A]. There was also no difference in the percent of double-labeled cells 
[U(56, 80) = 25.00, p = 0.63, Figure 27B].  
Fluorescence. There was no difference in the number of BrdU+GFAP+ cells when 
counted in fluorescence [t(10) = 7.13, p = 0.49, Figure 27C]. There was also no difference in 
the percentage of new astrocytes [U(38, 40) = 17.00, p = 0.93, Figure 27D]. The average 
percent of new GFAP+ SGZ cells is commonly 10-12 percent (Steiner et al., 2004). In both 
control and cirazoline-treated mice in chromogen and fluorescence, we found only 4-5 
percent of new cells 4 wks after BrdU were GFAP+ astrocytes. These results suggest that 
chronic α1AAR activation via cirazoline does not change the number or percent of new cells 
that differentiate into mature astrocytes. 
Discussion 
Our results show there is no change in survival or differentiation of new cells in the 
adult mouse dentate gyrus after treatment with the α1AAR agonist cirazoline. Previously, in 
vitro culture with adult-derived neurospheres from the SVZ induced cells to differentiate 
into glial cells (Gupta et al., 2009). SVZ-derived and SGZ-derived neurospheres, theoretically, 
should both be the same type of neural stem cell therefore culturing and reacting to stimuli  
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Figure 27. Mature astrocytes. With chromogen labeling and counting in brightfield with stereology, 
there was no statistically significant difference between control and cirazoline-treated groups in the 
A) total number of BrdU+GFAP+ cells (p = 0.95) or the B) percent of cells double-labeled 4 wks after 
BrdU injection (p = 0.63). Similarly, there was no difference between groups in the C) number (p = 
0.49) or D) percent (p = 0.93) of matured astrocytes when counted in epifluorescence without 
stereology. Representative images are shown for E) control and F) cirazoline mice. Arrowhead shows 
double-labeled cells, arrow shows single-labeled BrdU cells. 
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similarly. However, the SGZ-derived neurospheres may have responded differently. Some 
labs have claimed to culture SGZ-derived cells without contamination from the nearby SVZ 
but it is currently controversial (Walker and Kempermann, 2014; Devesa et al., 2014; Jhaveri 
et al., 2014). One study treated SGZ-derived neurospheres with cirazoline or prazosin and 
did not show a difference in the proportion of cells differentiating into neurons (βIII-tubulin) 
or astrocytes (GFAP) (Jhaveri et al., 2014). This report did not assess differentiation in vivo. 
The lack of a change in the number or percent of BrdU+ cells after 4 wks suggests 
that α1AAR treatment does not increase, and may decrease, cell survival. Sixty percent of 
newly generated cells in the adult mouse do not survive past two wks (Dayer et al., 2003). 
An assay of activated caspase 3 (AC3) or TUNEL for apoptotic cell death would be another 
way to assess cell survival. It is possible that α1AAR activation could be inducing division of 
neural stem cells rather than neural progenitor cells. In that case, it is possible the stem cell 
pool was exhausted leading to an apparent decrease in survival (Ables et al., 2010). To 
address this, Nestin GFP mice could be used to count Type 1 (NSC) and Type 2 (NPC) cells by 
morphology and determine whether Type 1 cells are decreased after chronic α1AAR 
activation.  
In addition, we previously showed that cirazoline treatment increases the density of 
BrdU+ cells in the adult mouse dentate gyrus, which could have confounded our results in 
the current study (Gupta et al., 2009). Because cirazoline treatment began 4 wks prior to 
BrdU injection, a higher number of proliferating cells in the cirazoline-treated group were 
likely labeled. The percentage of cells labeled with both BrdU and DCX partially addresses 
this and boosts the finding that α1AAR activation did not affect cell survival. To confirm, 
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future studies should include a paradigm in which control and cirazoline-treated groups are 
injected with BrdU at a 2 hr timepoint and a separate cohort of mice injected and allowed 
to survive for 4 wks. Comparison of the number of BrdU+ cells at 2 hr and 4 wks would 
better address the question of whether α1AAR activation influences cell survival.  
DCX is often used as a proxy for BrdU as a measure of proliferation because it labels 
only immature neurons. Surprisingly, there was no difference in the number of DCX+ cells in 
the cirazoline-treated group. There was, in fact, a trend toward fewer DCX+ cells after α1AAR 
treatment and the effect size of these results was very large. Additional control animals to 
reduce the variability in that group would clarify these findings.  
Our previous work showed a higher density of BrdU+ cells in the SGZ. For a better 
comparison, density of DCX+ cells in the current samples could be analyzed but would 
require confocal-quality fluorescent imaging of the samples to accurately determine the 
dentate gyrus volume. Another possibility is that chronic cirazoline treatment accelerated 
the maturation of new cells which resulted in lower numbers of DCX+ cells after 4 wks (David 
et al., 2009; Wang et al., 2008). If that was the case, we would expect a higher number of 
either mature neurons or astrocytes, which was not seen. It is also possible that 
differentiation of the immature neurons was stunted, keeping them in an immature state. 
Approximately 25 percent of adult-born cells are of an unknown phenotype so there is a 
remote possibility that cirazoline increased cell fate toward an unknown phenotype. As yet, 
it is not possible to answer this question. 
Our hypothesis was that cirazoline would push differentiation toward astrocytes 
rather than neurons. There was no difference in the number or percent of cells that were 
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BrdU+GFAP+ vs BrdU+NeuN+. The percent of new neurons was similar to published research 
but the percent of new GFAP+ astrocytes was half of what previous studies have found. This 
could be due to the difficulty of quantifying double-labeling of BrdU and GFAP in brightfield 
and epifluorescence. Imaging with confocal-like quality would alleviate this issue. To confirm 
the finding of astrocytes, double-labeling for BrdU and S100β would be informative. Most 
GFAP+ cells 4 wks after BrdU administration are also S100β+ (Steiner et al., 2004). In 
addition, S100β does not label neural stem cells, which may provide a more accurate 
assessment of differentiated cells.  
The results of the current study are interesting and important despite the lack of 
statistical significance. The large effect size of the DCX results coupled with the trend toward 
fewer BrdU+DCX+ cells implies a potential effect of chronic α1AAR activation on the rate of 
differentiation. Coupled with our previous work showing an increase in the density of BrdU+ 
cells in the SGZ of CAM-α1AAR mice, this could mean that the proliferating cells are kept in 
the immature neuron state rather than continuing through differentiation. In recent years, 
the field of adult neurogenesis and learning has shown an importance for adult-born cells 
not surviving past the first few weeks (Denny et al., 2012; Drew et al., 2013). These new cells 
have increased plasticity and are important for retaining memories, particularly during 
pattern separation. If chronic α1AAR activation is indeed keeping cells in this immature state, 
it could potentially explain the enhancements in learning and memory we have previously 
reported (Doze et al., 2011).  
Overall, our results suggest that α1AAR activation does not affect survival or the final 
cell fate in the adult mouse dentate gyrus during adult neurogenesis. In the future, 
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additional animals and the proposed experiments could clarify the effect of cirazoline on cell 
survival and differentiation. 
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CHAPTER 5 
 
LONG-TERM ALPHA1B-ADRENERGIC RECEPTOR ACTIVATION SHORTENS LIFESPAN WHILE 
ALPHA1A-ADRENERGIC RECEPTOR STIMULATION PROLONGS LIFESPAN IN ASSOCIATION 
WITH DECREASED CANCER INCIDENCE 
 
Abstract 
The α1-adrenergic receptor (α1AR) subtypes, α1AAR and α1BAR, have differential 
effects in the heart and central nervous system. Long-term stimulation of the α1AAR subtype 
prolongs lifespan and provides cardio- and neuro-protective effects. We examined the 
lifespan of CAM-α1BAR mice and the incidence of cancer in mice expressing the 
constitutively active mutant (CAM) form of either the α1AAR (CAM-α1AAR mice) or α1BAR. 
CAM-α1BAR mice have a significantly shortened lifespan when compared with wild type 
(WT) animals; however, the effect was sex dependent. Female CAM-α1BAR mice lived 
significantly shorter lives while the median lifespan of male CAM-α1BAR mice was not 
different when compared with WT animals. There was no difference in the incidence of 
cancer in either sex of CAM-α1BAR mice. The incidence of cancer was significantly decreased 
in CAM-α1AAR mice when compared with WT and no sex dependent effects were observed. 
Further study is warranted on cancer incidence after activation of each α1AR subtype and 
the effect of sex on lifespan following activation of the α1BAR. The implications of a 
decrease in cancer incidence following long-term α1AAR stimulation could lead to improved 
treatments for cancer. 
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Introduction 
Epinephrine and norepinephrine are catecholamines that act as chemical 
messengers. They are synthesized in the adrenal medulla and in adrenergic neurons in the 
brain, respectively, as well as in post-ganglionic neurons in the sympathetic nervous system. 
In the periphery, both epinephrine and norepinephrine help regulate heart rate and blood 
vessel constriction and modulate the force of heart contraction and physiological arousal. 
When stressed, the body releases both chemicals to mediate the fight-or-flight response. All 
of these effects are a result of epinephrine or norepinephrine binding to adrenergic 
receptors (ARs), of which there are three families: α1, α2, and β.  
Our lab has found differential effects of activating either the α1A or α1BAR subtype. 
Long-term stimulation of the α1AAR, either pharmacologically or through transgenic 
manipulation, increases adult neurogenesis, reduces depression and anxiety-like behavior, 
and enhances learning and memory in the mouse (Gupta et al., 2009; Doze et al., 2011, 
2009). Mice with a constitutively active mutant form of the α1AAR (CAM-α1AAR) also live 
significantly longer lives when compared with wild type (WT) animals of the same 
background (Doze et al., 2011). In contrast, chronic activation of the α1BAR increases 
depression-like behavior (Doze et al. 2009). Chronic α1BAR activity also leads to age-related 
apoptotic neurodegeneration, a synucleinopathy with Parkinson-like movement deficits 
similar to human multiple system atrophy (Papay et al., 2002; Zuscik et al., 2000). The 
neurodegeneration begins in areas of the brain with a high density of α1BARs and leads to a 
substantial loss of dopaminergic neurons in the substantia nigra. The α1AR-selective 
antagonist terazosin protects against α-synuclein aggregates, neurodegeneration, and 
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partially rescues the movement deficits. Terazosin treatment also ameliorated the α1BAR 
activation’s detrimental effect on early mortality; however, animals were only followed up 
to 70 wks of age. Taken together, these results suggest the α1AR subtypes mediate 
neurogenesis and neurodegeneration which is in line with their role in proliferation in the 
peripheral nervous system.  
The α1ARs can mediate proliferation and cell growth in the periphery (Michelotti et 
al., 2000; Hoffman and Hu, 2000). α1AR activation stimulates DNA synthesis in human 
vascular smooth muscle cells through a PI3 kinase and MAPK pathway (Hu et al., 1996; 
Hoffman and Hu, 2000). It also induces the expression of the proto-oncogenes c-fos and c-
jun in arterial smooth muscle (Okazaki et al., 1994). In a Rat-1 fibroblast microarray, the 
α1AR subtypes preferentially induced transcription of genes that regulate the cell cycle 
(Gonzalez-Cabrera et al., 2004). The microarray results suggested α1A and α1DARs halt the 
cell cycle at the G1-S checkpoint. α1BAR expression led to cell cycle progression through the 
G1-S checkpoint by inducing transcription of cdk-6- and cyclin E-associated kinases. This cell 
cycle progression is evident in Rat-1 and NIH-3T3 fibroblast cells transfected with α1BARs 
which enhances focus formation after agonist stimulation. The cells are also tumorigenic 
when injected into nude mice, implicating the gene as a potential proto-oncogene (Allen et 
al., 1991; Gonzalez-Cabrera et al., 2004). That is the only study to date that has examined in 
vivo tumor formation mediated by the α1AR subtypes. The role of the α1AAR subtype in 
cancer incidence has not been examined prior to the current study. 
Our hypothesis was that long-term transgenic activation of the α1A and α1BARs 
would lead to a decrease and increase in the incidence of cancer, respectively. It was 
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expected that chronic activation of the α1BAR would lead to a shorter lifespan due to cancer 
and neurodegeneration. In this study, we followed transgenic mice overexpressing the α1A 
or α1BAR throughout their lifespan. We also completed necropsy on subsets of each group 
to assess cancer incidence. Surprisingly, we found that chronic α1BAR activation had no 
significant effect on cancer but did reduce longevity, presumably secondary to increased 
neurodegeneration. Importantly, we observed that long-term α1AAR stimulation was 
associated with a significantly lower incidence of cancer and longer lifespan. 
Methods 
Animals 
This study used transgenic mice overexpressing a constitutively active mutant (CAM) 
form of either the α1A or α1BAR that were created on a B6CBA background. The CAM 
receptor genes were expressed under the endogenous promoters and the animals have 
been previously characterized (Zuscik et al., 2000; Rorabaugh et al., 2005). The longevity 
part of the study included 235 mice and the pathology study included 157 mice with some 
overlap. Animals were bred and provided with identifying ear tags at the Cleveland Clinic 
Foundation and transferred to the University of North Dakota. Both facilities are accredited 
by the Association for Assessment and Accreditation of Laboratory Animal Care (AAALAC). 
The experimental protocols employed in this study conform to the Guide for the Care and 
Use of Laboratory Animals, published by the US National Institutes of Health, and were 
approved by the Animal Care and Use Committee at both institutions.  
Mice were housed in translucent, polycarbonate boxes, 17 × 28 × 13 cm, 1-5 mice 
per box with one rodent clubhouse. Animals were maintained on a 12 h light-dark cycle 
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with lights on at 0700. Harlan diet 8640 and water were provided ad libitum (Harlan, 
Indianapolis, IN). The temperature was held constant at 22 °C and the humidity at 23-27%.  
Longevity 
Animals were observed daily by facility personnel but handled only for cage changes 
and clinical assessments. All staff members who observed and handled the mice were 
trained to detect and record signs of illness and notified the veterinarian and research team 
immediately regarding sick animals. The veterinarian and researchers examined the mice 
for severity of illness or impairment and animals were euthanized if they were not likely to 
survive for another 48 h. The likelihood of survival was based on the occurrence of at least 
two of the following clinical signs set forth by The Jackson Laboratory (Yuan et al., 2009). 
The signs included: failure to drink or eat; extreme weight loss over a short period of time; 
severe weakness based on responsiveness to touch; serious locomotor impairments; or 
tumors that had ulcerated or were bleeding (Ray et al., 2010). The date of death for each 
mouse was logged and the number of days lived was calculated and used for analysis. The 
mean age at death for the euthanized mice was not significantly different from the mice 
which died spontaneously, therefore euthanized mice were included in the analysis.  
Pathology 
Mice were removed from their cages as soon as possible after death and frozen at -
20 °C until pathological analysis. Animals sacrificed at a younger age were included in the 
analysis to increase statistical power (See Appendix A for further information). At necropsy, 
the mice were visually inspected and the exterior palpated to assess skin condition and any 
outward signs of abscess, disease, or tumors. The abdomen and thoracic cavities were 
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opened and organs inspected and removed. Tumors were digitally photographed in situ and 
after removal with a measurement scale clearly visible. Samples of the heart, lungs, spleen, 
kidney, liver, and intestine were immersion-fixed in neutral buffered 10% formalin for at 
least 24 h. Samples were dehydrated in graded ethanol, cleared in xylene, infiltrated, and 
paraffin embedded. Serial sections were cut at 3-5 μm, stained with hematoxylin and eosin, 
and evaluated for cancerous cells on a Carl Zeiss Axioskop 50 microscope (Zeiss, Germany). 
Classification of tumors was based on the current World Health Organization Classification 
of Tumors with modifications, as needed, for mouse tissue. The primary diagnosis for each 
animal was used for analysis; tumor burden was not assessed.  
Statistical Analysis 
Survival was analyzed using Kaplan Meier survival curves and the log-rank (Mantel-
Cox) test with GraphPad Prism 5.04 (San Diego, CA). The median lifespan was the point at 
which the fractional survival of each curve equaled 50 percent. Cancer incidence was 
analyzed using a 2 test on raw data but is presented as percentages for clarity. Mice still 
alive at the end of the study were interval-censored. An unpaired t-test was used for 
comparison of maximal lifespan. Significance levels were set at p < 0.05. 
Results 
Chronic Activation of the α1BAR Leads to Decreased Body Weight Starting During Middle 
Age While Long-Term α1AAR Stimulation Does Not Affect Adult Weight 
 
We weighed cohorts of mice at various ages to rule out increased lifespan due to 
caloric restriction because acute activation of the α1AAR can suppress appetite (Davies and 
Wellman, 1992; Morien et al., 1993). Just after weaning, CAM-α1AAR (p < 0.05) and CAM-
α1BAR mice (p < 0.001) weighed significantly less than WT mice (Figure 28). Between the 2
nd 
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Figure 28. Weight across the lifespan. CAM-α1BAR mice weighed significantly less than WT mice at 
most time points after 9 mo of age * p < 0.05, ** p < 0.01, *** p < 0.001 
 
mo and the end of the 8th mo of age there were no significant differences in weight 
between groups. However, CAM-α1BAR animals weighed significantly less when compared 
with WT mice starting at approximately 9 mo of age. The 21-24 mo age range had a low 
number of CAM-α1BAR animals and no significant differences in weight were observed.  
CAM-α1AAR Mice Have an Increased Lifespan While CAM-α1BAR Mice Have Shorter Lives 
We previously reported that CAM-α1AAR mice have a significant increase in median 
and maximal lifespan when compared with WT animals (Doze et al., 2011). The CAM-α1AAR 
longevity data included here is the previously published data and is included only for 
comparison. There was no significant difference between lifespans of previously published 
WT animals and WT mice that have died since; therefore, both groups are included here to 
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provide statistical power (Figure 29, Table 3, Appendix A). Comparison of WT mice excluding 
previously published data and CAM-α1BAR mice can be found in Appendix A.  
Within the WT group, there was no significant difference between female (711 d) 
and male mice (721 d, 2 = 2.300, df = 1, p = 0.129). The median lifespan of CAM-α1BAR mice 
(637 d) was significantly shorter than WT animals (719 d, 2 = 7.194, df = 1, p = 0.007), a 
decrease of approximately 11% (Figure 29, Table 3). There was no significant difference in 
lifespan between the male CAM-α1BAR mice (652 d) and male WT animals (721 d, 
2 =0.251, 
df = 1, p = 0.616). Female CAM-α1BAR mice (619 d) lived significantly shorter lives than 
female WT animals (711 d, 2 = 9.415, df = 1, p = 0.002).  
Maximal lifespan is an index of slowed aging and is calculated by comparing the ages 
of the 10% longest living mice in each group. The maximal lifespan of CAM-α1BAR mice was  
significantly shorter than WT mice (p = 0.025). Female CAM-α1BAR mice had a significantly 
shorter maximal lifespan than female WT animals (p = 0.009). However, the maximal 
lifespan of male CAM-α1BAR mice was significantly increased when compared with male WT 
mice (p = 0.004).  
The sigmoidal shape of all three survival curves suggests deaths were not due to a 
terminal infectious agent or a disease causing rapid death (Van Zwieten et al., 1981). The 
CAM-α1BAR curve begins to deviate from the WT curve at approximately 9-10 mo (270-300 
d) of age suggesting normal development to that point. The longest living CAM-α1BAR 
animals lived to similar ages as WT animals, likely due to incomplete penetrance of the 
99 
 
Figure 29. Kaplan-Meier survival plots. CAM-α1BAR mice (n = 87) have a shorter lifespan than WT 
mice (n = 112, p = 0.007). As previously published, CAM-α1AAR animals (n = 36) live significantly 
longer than WT mice (p = 0.004) (Doze et al., 2011). 
 
transgene in those animals. Similarly, the CAM-α1AAR curve shifts closer to WT at the end of 
life stage.  
Chronic α1BAR Stimulation Has No Significant Effect on the Incidence of Cancer While 
Activating α1AARs Decreases Cancer Incidence 
 
The overall cancer incidence between CAM-α1BAR (n = 34) and WT mice (n = 70) did 
not differ (2 = 0.1242, df 1, p = 0.7245, Figure 30). In contrast, CAM-α1AAR mice (n = 53) 
had a significantly lower overall incidence of cancer than WT animals (n = 70) (2 = 17.83, df 
1, p < 0.0001). There was no significant difference in cancer incidence between male and 
female animals for any of the groups.  
The most common diagnoses among WT mice were epithelial and hematological 
cancers (Table 4). CAM-α1AAR and CAM-α1BAR animals had a similar incidence for the type  
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Table 3. Lifespan data of CAM-α1BAR, WT, and CAM-α1AAR mice 
 
Genotype Median 
(d) 
Mean 
(d) 
S.D. 
(d) 
S.E.M.  
(d) 
95% CI  
(d) 
90th Percentile 
(d) 
Deaths 
(n) 
        
CAM-α1BAR 637 617 200 21 575 - 660 890 87 
Male 652 635 204 29 576 - 694 907 48 
Female 619 595 196 31 532 - 659 882 39 
        
Wild type 719 689 203 19 651 - 727 912 112 
Male 721 674 195 28 618 - 729 875 50 
Female 711 701 210 27 648 - 754 932 62 
        
CAM-α1AAR 819 806 146 24 757 - 856 982 36 
Male 822 821 150 35 746 - 895 999 18 
Female 819 792 145 34 720 - 864 928 18 
 
of cancers as WT mice. Epithelial cancers included adenocarcinoma of the lung, renal cell 
carcinoma, hepatocellular carcinoma, and neuroendocrine carcinoma. Hematological 
cancers included lymphoma and leukemia involving various organs. The only mesenchymal 
cancer was spindle cell sarcoma. Non-cancerous epithelial lesions included hepatocellular  
and small intestine adenomas and one case of hepatocellular hyperplasia. The only non-
cancerous hematological finding was lymphoid hyperplasia. Mesenchymal tumors included 
hemangioma and a non-cancerous fibroma. Non-tumor lesions included pathologies such as 
pulmonary edema, chronic inflammation, glomerular disease, cardiomyopathy, and heart 
thrombi. Representative images of common diagnoses are shown in Figure 31.
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Figure 30. Cancer incidence. CAM-α1AAR (n = 53) mice had a significantly lower incidence of cancer 
when compared with WT animals (n = 70, p < 0.0001). The incidence of cancer in CAM-α1BAR mice 
did not differ from that of WT mice (n = 34, p = 0.7245). 
 
Discussion 
It is well documented that caloric restriction increases lifespan in many species 
including rodents (Reviewed in Masoro, 2005). Injection of α1AR agonists systemically or 
into the paraventricular nucleus of the hypothalamus can cause appetite suppression in 
acute studies (Davies and Wellman, 1992; Morien et al., 1993). In our lab, long-term 
treatment (8-9 wks) with cirazoline, an α1AAR-selective agonist, has not reduced food or 
water intake nor reduced body weight (Doze, Goldenstein, and Collette, unpublished data). 
To our knowledge, food intake has not been studied in CAM-α1AAR or CAM-α1BAR mice. 
However, because even modest caloric restriction can reduce body weight we weighed 
cohorts of mice to determine whether transgenic activation of either α1AR subtype 
decreased body weight with a subsequent increase in lifespan (Colman et al., 2009). There 
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Table 4. Pathology of WT, CAM-α1AAR, and CAM-α1BAR mice at death 
 
 
B6CBA WT  
(n = 70) 
CAM-α1AAR  
(n = 53) 
CAM-α1BAR  
(n = 34) 
 
Cancerous 
 
45.7% (32) 
 
13.2% (7) 
 
38.2% (13) 
 Epithelial 25.7% (18) 5.7% (3) 23.5% (8) 
 Hematological 18.6% (13) 7.5% (4) 8.8% (3) 
 Mesenchymal 1.4% (1) 0.0% (0) 5.9% (2) 
 
Noncancerous 
 
54.3% (38) 
 
86.8% (46) 
 
61.8% (21) 
 Benign tumor    
 Epithelial 7.1% (5) 3.8% (2) 0.0% (0) 
 Hematological 2.9% (2) 3.8% (2) 11.8% (4) 
 Mesenchymal 0.0% (0) 3.8% (2) 2.9% (1) 
 Non-tumor lesions 35.7% (25) 49.1% (26) 35.3% (12) 
 No abnormal findings 8.6% (6) 26.4% (14) 11.8% (4) 
 
was no difference in body weight between CAM-α1AAR and WT mice except one timepoint 
after weaning. Body weight of the CAM-α1BAR animals was significantly lower when 
compared with WT mice after weaning and again after approximately 9 mo of age. 
However, the lifespan of CAM-α1BAR mice was decreased rather than increased so the 
effect was not positive on lifespan. Food intake was not assessed during the longevity study 
so we cannot definitively conclude that the α1AAR-stimulated lifespan increase was not 
through a caloric reduction mechanism but it seems unlikely because the CAM-α1AAR 
animals were of normal weight. 
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Figure 31. Representative photomicrographs of the most common pathological findings at death. A) 
Pulmonary edema in a CAM-α1AAR mouse, B) lymphoma in a WT mouse, C) adenocarcinoma in a WT 
mouse, and D) lymphoma of the lung in a CAM-α1BAR mouse. 
 
Previous studies of increased lifespan in mouse found a 15-80 percent extension, 
depending on the intervention (Blüher et al., 2003; Brown-Borg et al., 1996). Shortened 
lifespan is not reported as often but in certain transgenic models death in utero or within 
the early postnatal period is not uncommon if the mutated gene is involved in critical 
developmental processes (Thyagarajan et al., 2003). In our study, CAM-α1BAR mice had an 
11 percent decrease in lifespan when compared with WT animals but the cause of the 
decrease is still unknown. Some genetic models with shortened lifespan showed 
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accelerated aging or increased cancer incidence with subsequent lifespan decreases of 25-
50 percent (Rudolph et al., 1999; Keyes et al., 2005). We observed signs of accelerated aging 
including reduced body weight, alopecia, and spine curvature in our model but did not 
examine other factors such as bone density or cellular senescence (de Boer et al., 2002; Sun 
et al., 2004). Cancer incidence was similar to WT mice. Another factor which must be 
considered in mouse models of aging is the background strain because the baseline lifespan 
is variable. 
There have not been any studies yet on the lifespan of the B6CBA mouse, which is a 
cross between the C57BL/6 and CBA strains. The median age of C57BL/6 mice varies 
depending upon environment but ranges from 682-930 d (Ikeno et al. 2005; Selman and 
Withers 2011, and Reviewed in Nadon et al. 2008). In a study of 31 inbred strains at Jackson 
Labs, C57BL/6J mice had median ages of 866 d for males and 901 d for females (Yuan et al., 
2009). In the same study, CBA/J mice had median ages of 679 d for males and 644 d for 
females. Our WT B6CBA animals had a median age of 719 d, which is between the two 
strains, but slightly closer to the CBA/J median age.  
Prior to this work, survival had been assessed in CAM-α1BAR mice, then called T1 
mice, for up to 70 wks (Papay et al., 2002). However, no previous studies followed all 
animals until the natural date of death. In the current study, the survival of CAM-α1BAR 
animals began to deviate from WT mice at approximately 9 mo of age, the timing of which 
coincides with the pathological appearance of neurodegeneration and the age at which 
body weight begins to differ (Papay et al., 2002). The α1AR antagonist terazosin protects 
these mice against the weight loss and neurodegeneration. Terazosin also increased survival 
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rates in the T1 mice but the animals were not followed until natural death so the effect of 
terazosin on full lifespan is unknown. The combination of that study and the current results 
suggest the effects of α1BAR over-activation can cause a shortened lifespan. The α-
synucleinopathy induced by chronic activation of α1BARs is similar to multiple system 
atrophy (Zuscik et al., 2000; Papp et al., 1989). Multiple system atrophy can lead to early 
death in humans by sudden cardiopulmonary arrest or pneumonia (Papapetropoulos et al., 
2007). In our study, there was no increased incidence of either event in CAM-α1BAR mice. 
The mechanism by which α1BAR activation can decrease lifespan is still unknown. 
The sex differences in median and maximal lifespan in CAM-α1BAR mice were an 
unexpected result, particularly because cancer incidence was not different for either sex. 
However, we did not examine cancer progression over time, which could have clarified 
whether cancer in the female mice was more aggressive with a quicker latency to death. We 
have not found sex differences in other studies using the CAM-α1BAR mice (Doze et al., 
2009). There is a dearth of data on sex differences in general in the scientific literature and 
only one published study on sex differences in relation to the adrenergic receptors 
(Novakova et al., 2010). In this report, female mice had higher basal α1AR receptor densities 
in the lung and immobilization stress decreased the level of all three α1AR subtypes. In male 
mice, only the α1AAR level was decreased following stress. In the current study, shortened 
lifespan in the female CAM-α1BAR animals may have involved hormonal changes mediated 
by the α1BAR. There are noradrenergic innervations to the breast and ovarian follicles, 
where norepinephrine release can increase the levels of estradiol and progesterone and a 
decrease of sympathetic input can slow tumor growth (Romeo et al., 1991; Piccinato et al., 
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2012). Furthermore, the norepinephrine reuptake inhibitor desipramine promotes breast 
cancer progression with α2AR activation however, phenylephrine, a non-selective α1AR 
agonist, did not have an effect (Szpunar et al. 2013). It’s possible the α1BAR is involved in 
hormone-related cancer progression but further work should be done to clarify if there is a 
role for the receptor. 
The decrease in lifespan in the CAM-α1BAR mice is unlikely due to heart failure, 
which is not present in this mouse model. While animal studies suggest that chronic 
activation of the α1BAR subtype may be “bad” or maladaptive for the heart, the amount of 
dysfunction does not lead to heart failure if overexpression is more physiologically relevant 
or the heart is not stress-induced. CAM-α1BAR mice also have a mild cardiac hypertrophy, 
decreased cardiac output, some diastolic dysfunction, and inflammation. These conditions 
did not, however, progress to heart failure on their own (Zuscik et al., 2001; Yun et al., 
2003). Other groups have demonstrated that myocyte-targeted CAM-α1BAR also induces a 
mild hypertrophy when the receptor is only overexpressed 3-fold or less, as it is in our 
mouse model, but only progressed to heart failure after blood pressure overload (Milano et 
al., 1994). Therefore, chronic stimulation of the 1BAR leads to hypertrophy and some 
cardiac dysfunction but only induces heart failure when the receptor is artificially 
overloaded. As this aging study only used non-stressed mice, it is unlikely that CAM-α1BAR 
mice die younger because of heart failure. Furthermore, in the present study one case of 
heart-related dysfunction was noted in CAM-α1BAR mice, a heart thrombus. 
On the other hand, previous studies have suggested the CAM-α1AAR mice are cardio-
protected, which may contribute to its increased longevity (Reviewed in Perez and Doze 
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2011). While CAM-α1AAR mice also display cardiac hypertrophy as in CAM-α1BAR mice, 
α1AAR activation results in positive adaptation of the heart to protect against ischemic 
damage through preconditioning via cardiac protective IL-6 and JAK/STAT pathways or by 
preventing apoptosis due to increased glucose uptake (Rorabaugh et al. 2005; Papay et al. 
2013, Perez, unpublished data). In the current study, one case of heart dysfunction was 
found in CAM-α1AAR mice: endocarditis/ myocarditis. 
The decrease in lifespan in CAM-α1BAR mice does not appear to be due to an 
increase in cancer incidence. In vitro, α1BAR overexpression and activation results in focus 
formations (Allen et al., 1991). In addition, the cells form tumors when injected into 
immune-compromised mice. Due to the tumorigenic quality of transplanted α1BAR-
expressing cells, we hypothesized CAM-α1BAR mice would have an increased incidence of 
cancer. Surprisingly, there was no significant difference in cancer incidence between CAM-
α1BAR mice and WT animals. The α1BAR can regulate the cell cycle through cdk-6 and cyclin 
E-associated kinases but the α1BAR effect on proliferation may be cell type specific 
(Gonzalez-Cabrera et al., 2004). For example, in CHO cells transfected with the α1BAR the 
cell cycle was stopped when activated by phenylephrine (Shibata et al., 2003). In TRAMP 
cells which expressed mostly the α1BAR subtype, doubling time was faster with decreasing 
α1BAR and increasing α1AAR and α1DAR expression (Shi et al., 2007). However, the cancerous 
state is highly complex and does not solely depend on a dysregulation of the cell cycle. Ours 
is the first study to explore the effect of α1BAR activation in cancer in an immunocompetent 
mouse strain.  
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In most cell types studied, the α1AAR subtype increases the levels of the cdk inhibitor 
p27Kip1 and halts the cell cycle at the G1-S checkpoint (Gonzalez-Cabrera et al., 2004; 
Saeed et al., 2004; Shibata et al., 2003). In our study, there was a significant reduction in 
cancer incidence in CAM-α1AAR mice, which could be due to this cell cycle stoppage. The cell 
type specificity of α1AR subtype localization, downstream pathways, and subsequently 
physiological effects are imperative to the mechanism behind the reduction. For example, in 
human prostate cancer cells, the α1AR selective antagonist naftopidil stops growth through 
the same mechanism by which agonists halt the cycle, via p27Kip1 (Kanda et al., 2008). 
These contradictions are perplexing much as contradictory studies were prior to the 
delineation of the three α1AR subtypes. The answers may lie in the regulators of G-protein 
signaling (RGS), reactive oxygen species, and cell type specific downstream effects 
(Abramow-Newerly et al., 2006; Hu et al., 1999; Shi et al., 2006).  
Previous studies have implicated other ARs in longevity function, but these studies 
indicated shortened lifespan due to disease onset rather than increased lifespan. β2ARs 
promote aging and reduced lifespan mostly due to adverse effects on cardiac and 
pulmonary functions and its age-related impairment to regulate insulin secretion (Gao et al., 
2003; Santulli and Iaccarino, 2013; Santulli et al., 2012). However, it could also be due to 
polymorphisms in the receptor. For example, one study compared β2AR polymorphisms and 
found two variants that were associated with increased longevity in the Han Chinese 
population (Zhao et al., 2012). These polymorphisms reduced translational efficiency and 
receptor expression in transfected cells suggesting that decreased β2AR function promoted 
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longevity. In contrast, our results are the first to report that increasing AR activity would 
promote a longer lifespan, but specifically through the α1AAR subtype. 
Human longevity has continued to increase as sanitation, healthcare, and modern 
medicine have evolved. Ideally, increased longevity will also translate into improved health 
in later years. Cancer is one of the leading causes of death worldwide with approximately 
50% of cases occurring in persons older than 65 years of age. Current therapeutics are not 
ideal because they kill all dividing cells indiscriminately which can lead to uncomfortable 
and dangerous side effects. Preferential activation of the α1BAR subtype has negative effects 
in the heart and brain and may increase proliferation in some cell types, while stimulating 
the α1AAR shows positive effects in these areas. The current work is the first to show that 
chronic activation of the α1BAR can shorten lifespan. Whether this is due to accelerated 
neurodegeneration and/or other disease process(es) is still unknown. Importantly, we 
found that long-term α1AAR stimulation significantly decreases cancer incidence which may 
account in part for our previous finding that it increases lifespan. While more work is 
needed, it is clear that activating the α1AR subtypes leads to differential effects. α1AAR 
subtype-specific therapeutics may lead to improved cancer therapeutics with fewer adverse 
effects.  
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CHAPTER 6 
DISCUSSION 
There are several key findings herein on the role of α1AR subtypes in brain, and 
potentially peripheral, function. α1AAR activation does not influence survival and cell fate 
during adult neurogenesis. However, it does affect survival at the systemic level by 
increasing median and maximal longevity. Behaviorally, the lack of α1AAR function does not 
reliably change levels of anxiety or depression in relation to WT mice. In slightly older α1AR 
mice, anxiety levels are higher in the zero maze if the mice have not had seizures. Lack of 
α1BAR function reduces depression-like behavior but does not change anxiety-like behavior 
when compared with WT. Both KO groups had deficits in novel object recognition based on 
their memory of the original object failing to be higher than chance level. Lack of α1A- or 
α1BAR function does not change spatial memory or cognitive flexibility in the Morris water 
maze. Despite this, α1AAR-KO mice did not significantly increase path efficiency over the 
course of testing. Overall, the combined results are an important step in determining the 
role of α1AR function.  
Contribution to the field 
The field of α1ARs and brain/ behavioral function was previously limited by the use 
of non-selective agonists and antagonists that cross the blood brain barrier. Though 
activation and KO mouse models have been available for over a decade, they are 
predominantly used to study cardiac and cardiovascular function in the periphery. Our work
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 with transgenic animals is currently the leading research in the field in the area of brain and 
behavioral function of α1ARs. In the context of adult neurogenesis, norepinephrine is the 
only main neurotransmitter in which the function has not been studied in depth. No other 
lab has published research regarding the effect of the α1AR subtypes’ role in differentiation 
in vivo. Additionally, previous research suggested the α1BAR as a proto-oncogene based on 
in vitro work and subcutaneous injection of cancer cells (Allen et al., 1991). Our results show 
this does not appear to translate to the whole animal. Therefore, the research presented in 
this dissertation added a significant amount of new knowledge and proposes new avenues 
for study based on this knowledge. 
Learning and memory 
The role of the α1AR and α1AAR subtypes in learning and memory has not been clear 
and has been somewhat controversial due to conflicting results. Research examining the 
role of the receptors in prefrontal cortex-based learning and memory suggests that α1ARs 
and even the α1AAR subtype may be detrimental to learning and memory (Gibbs and 
Summers, 2001; Gibbs and Bowser, 2010; Mao et al., 1999; Arnsten et al., 1999; Arnsten 
and Jentsch, 1997; Torkaman-Boutorabi et al., 2014). The role of the receptor subtypes 
could be region-based: activation in the prefrontal cortex could be disruptive while 
activation in the hippocampus is enhancing. However, many of the studies that found 
deficits used only acute administration of agonists and antagonists, and they were mostly 
not selective for the receptor subtypes. In an early study with α1BAR-KO mice, KO enhanced 
object recognition memory but impaired spatial memory when compared with WT mice 
(Spreng et al., 2001).  
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Our prior research showed that chronic α1AAR activation, either using cirazoline or 
CAM activation of each subtype, enhanced both learning and memory in several measures. 
Our hypothesis for the experiments herein was that KO of the α1AAR subtype would worsen 
learning and memory measures; a hypothesis that was not upheld by the results except in 
the novel object recognition test. We also hypothesized that α1BAR-KO would mirror the 
learning and memory results of the Spreng study: enhanced novel object recognition but 
impaired spatial memory (Spreng et al., 2001). Instead, we found impaired novel object 
recognition (though not in relation to WT) and no difference in spatial memory compared 
with either the WT or α1AAR-KO mice. A limitation of using KO mice is the potential for other 
pathways to compensate for the missing receptor. To confirm the findings presented 
herein, further research could use α1AR subtype-selective antagonists via a ventricular 
cannula or a conditional KO mouse model. However, in combination with the conflicting 
mood results, the possibility that the α1AR subtypes interact to mediate behavioral effects is 
intriguing.  
Depression and anxiety 
Depression and anxiety are highly intertwined and often comorbid in humans. While 
the α1AR subtypes have not been previously studied in the context of depression and 
anxiety by other labs, there is evidence for α1AR involvement in the mechanism of 
antidepressant action. Antidepressants with α1AR antagonist properties can block anxiety 
and depressive-like behavior in animal models (Danysz et al., 1986; Kakui et al., 2009; Kitada 
et al., 1983). The α1AR agonist, phenylephrine, potentiates the effect of the atypical 
antidepressant lamotrigine (Puumala et al., 1996). Furthermore, α1AR subtype activation 
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increases the density of α1A- and α1BARs in specific brain regions (Hanft and Gross, 1990; 
Perry et al., 1990).  
Our earlier research showed that chronic α1AAR activation decreases the basal level 
of depression and anxiety when compared with WT mice. Based on these results and the 
work of others, we hypothesized that α1AAR-KO mice would have increased levels of 
depression and anxiety-like behaviors when compared with WT and α1BAR-KO mice would 
have decreased  levels of depression. We did not expect a difference in anxiety behavior in 
α1BAR-KO mice in comparison to WT mice because we had seen no differences in anxiety 
after α1BAR activation. The results were interesting. α1AAR-KO did not change anxiety levels 
except in one test after removing mice that had experienced seizures. α1BAR-KO mice had 
increased anxiety-like behavior in one parameter of the elevated zero maze compared with 
WT but a decreased depression level. Because depression and anxiety are inter-related, 
these conflicting results are difficult to interpret. One main difference between the CAM 
transgenic mice and the KO mice is that in the CAM mice both receptors are still present but 
at differing ratios of expression and activation. One explanation for the behavioral results of 
the current studies is that of in vivo receptor heterodimerization. This idea that the 
receptors dimerize to affect function and surface expression is particularly intriguing when 
exploring the mood results. This will be an important avenue in future research and is 
already being pursued in at least one other lab (Collette, personal communication).  
In order to make strong conclusions about using α1AAR activation as a treatment for 
depression additional research must be undertaken. Our previous and the current research 
show α1AAR activation does, while α1AAR-KO does not, change basal levels of depression. 
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Future research needs to include more ethologically valid experiments. One such possibility 
is to use a chronic mild stress paradigm to induce depression in rodents to model stress-
induced depression in humans. Treatment could include a selective α1AAR agonist or 
antagonist into the lateral ventricles via a cannula. Behavioral testing would show whether 
activation can rescue a depression phenotype or if blocking α1AAR function would further 
increase depression behaviors.  
Adult neurogenesis 
Chronic activation of the α1AAR in vitro and in vivo increases proliferation and directs 
cell fate in neurosphere culture (Gupta et al., 2009). Neurospheres cultured from normal 
adult mouse SVZ stimulated with phenylephrine, an α1AR agonist, induces differentiation 
into glial cells. Neurospheres isolated from neonatal CAM-α1AAR transgenic mice increases 
the differentiation markers Dlx2, Mash1, and NeuroD. Neurospheres from α1AAR-KO mice 
increase expression of Nestin, a stem cell marker, suggesting a reversion to a less 
differentiated state. In contrast, a recently published paper used SGZ-derived neurospheres 
to study the role of adrenergic receptors on proliferation and cell fate (Jhaveri et al., 2014). 
Successfully deriving neural stem cells from the hippocampus without SVZ contamination is 
highly controversial. However, using cirazoline on the neurospheres, there was no 
difference in the percentage of cells differentiating into astrocytes (S100β). They also did 
not see an increase in the number of new neurons (using βIIItubulin as a marker).  
The work presented herein examined the differentiation and survival stages of adult 
neurogenesis in vivo. Based on prior results, we hypothesized that newly created cells 
would differentiate preferentially into astrocytes rather than neurons in the adult mouse 
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SGZ. We found no difference in the number or percentage of new cells that became mature 
neurons, BrdU+NeuN+, or astrocytes, BrdU+GFAP+. There was a large effect size but no 
significant reduction in the number of immature neurons, BrdU+DCX+ cells 4 wks after BrdU 
injection. A reduction in immature neurons at this timepoint could mean that the rate of 
differentiation was faster after cirazoline treatment. If that was the case, the number of 
new mature neurons, BrdU+NeuN+, or astrocytes, BrdU+GFAP+, should have been increased 
and it was not. Taking the lack of increase in mature cell markers into account, it is also 
possible the rate of differentiation was decreased and newly generated cells did not 
progress past the immature neuron stage. This is also not likely because the percentage of 
mature neurons and astrocytes would have been decreased in the cirazoline group 
compared with controls and it was not. Analysis of DCX morphology of double-labeled cells 
could potentially answer this question. A better way would be to perform a time course of 
BrdU injections and cell counts. It is clear from the BrdU+NeuN+ and BrdU+GFAP+ results that 
the ratio of new cells is unchanged by chronic α1AAR activation but the DCX results are very 
interesting and should be further studied.  
Longevity and cancer 
Ours is currently the only published research regarding the α1AR subtypes and 
longevity (Collette et al., 2014). Survival to a 70 wk timepoint in another study was reduced 
to 75 percent in CAM-α1BAR mice (Papay et al., 2002). In the current study, the number of 
early deaths in the CAM-α1BAR was not quite that drastic but lifespan was significantly 
reduced compared with WT mice. One of the pioneers of AR research, Robert Lefkowitz, 
previously proposed that the α1BAR was a proto-oncogene (Allen et al., 1991). This was 
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based on his lab’s work showing that α1BARs formed foci when transfected into cells and 
tumors when injected subcutaneously into nude mice. In addition, the α1BAR gene is 
associated with mitogenesis and cell cycle progression, which could lead to cancer 
(Gonzalez-Cabrera et al., 2004). The results herein, show that the in vivo picture is more 
complex. Chronic activation of the α1BAR over the lifespan does not increase cancer 
incidence but it does decrease lifespan (Collette et al., 2014). Cancer is the most common 
cause of death in aged mice but our results show that activation of the α1BAR is not 
responsible but could be contributing. CAM-α1BAR mice develop a synucleinopathy similar 
to multiple system atrophy in humans which includes locomotor deficits, synuclein 
aggregates and neurodegeneration, autonomic dysfunction, and ultimately death (Papay et 
al., 2002). The decrease in lifespan after α1BAR activation is likely due to this 
neurodegeneration but this was not tested in the current study.  
Chronic α1AAR activation in CAM-α1AAR mice increases lifespan and significantly 
decreased cancer incidence in our population, which included mice at the end of life and a 
small number of younger mice. In this case, the correlation between increased lifespan and 
decreased cancer is an especially exciting finding and should be pursued. A potential 
mechanism could be regulation of the cell cycle by the α1AAR subtype. In a gene microarray 
using Rat-1 fibroblasts, α1AARs were associated with cell cycle regulators that stop the cell 
cycle at the G1-S checkpoint (Gonzalez-Cabrera et al., 2004). Important factors to consider 
when expanding this line of study include using a prospective, rather than retrospective 
analysis of lifespan and cancer; removing confounding variables such as behavioral testing; 
and use transgenic animals of the same F generation (Appendix A). It would also be 
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interesting to use mice that already have cancer and treat with an α1AAR agonist or 
antagonist. In studying peripheral cancers, such as in the present study, there is not a need 
for a drug to cross the blood brain barrier. The lab is now investigating the incidence of 
cancer in α1AAR-KO and α1BAR mice. The current study is a promising lead on a potential 
cancer prevention therapy in high-risk populations and expansion of this research would 
show whether it could also be used to stop cancer progression. 
Conclusions 
The progression of AR research has been akin to a funnel. Early on, it became clear 
there were different types of receptors with different downstream effects. It was thought 
that studying each of these types of receptors would clarify their roles in the body. 
However, it did not. Soon after, the subtypes were introduced but were difficult to study 
because there were no selective drugs. When drugs were developed they did not cross the 
blood brain barrier. Localization of the subtypes in the brain was even limited because there 
were not, and still are not, selective antibodies. The studies presented herein are an 
important step forward because they show the complexity of the α1AR subtypes and 
suggest another level of specification. ARs are regulated by many factors including such 
basic input as how tightly an agonist binds which can activate a different G-protein. Future 
work will continue to whittle down the differences and explore how to best utilize the ARs 
as therapeutic targets. Our work suggests that α1AAR-selective agonists could be promising 
treatments for diseases with cognitive disruptions, depression, anxiety, and even 
prevention of cancer. α1BAR-selective antagonists may prevent synucleinopathic 
neurodegeneration and could be used in conjunction with α1AAR agonists for depression. 
APPENDIX 
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APPENDIX A 
Lifespan, Cancer, and Loss of Phenotype 
Data Collection 
Data collection for the longevity study began prior to my arrival in the Doze lab; 
however, I did the majority of the data collection. I also verified dates of birth and death of 
all mice using mortality logs from the Center for Biomedical Research, shipment sheets from 
Cleveland Clinic, and cage cards. In some cases, there were mice with different birth dates 
in the same cage so if they did not have an ear tag at death they were not included because 
there was no way to verify the number of days lived.  
Retrospective Analysis 
The longevity study was a retrospective analysis of mice used in various behavioral 
studies over the span of several years. The mice were not included in any seizure studies 
nor were they given any treatments or drugs. A small retrospective analysis may be 
appropriate to provide data for a power analysis to determine how many animals would be 
needed for a full prospective study. However, standard procedure for a lifespan study is to 
predetermine the number of animals per group from the same F generation of breeding and 
begin tracking lifespan when they are the same age. Equal numbers of male and female 
mice would allow for reliable determinations of sex differences. Additionally, all 
confounding variables possible should be eliminated including behavioral testing. The mice 
should be allowed to age, undisturbed except for cage changes and food and water intake 
assessment, for their full lifespan. 
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Regarding Previously Published Lifespan Data 
Previously published wild type (WT) mouse lifespan data was included in analysis for 
additional power. There was no significant difference between WT data that had been 
previously published and WT data gathered for additional WT mice (Doze et al., 2011). 
However, the data excluding the previously published WT data is presented here for 
completeness (Figure 32). When comparing only the non-published WT and CAM-α1BAR 
lifespan there is not a significant difference in the number of days lived (χ2(1) = 1.83, p = 
0.055).  
Loss of Phenotype 
During analysis of the longevity and pathology data, we had initially planned to 
include additional CAM-α1AAR mice that had died since our 2011 publication, as we did with 
the WT data. However, I noticed a pattern that CAM-α1AAR mice received from Cleveland 
Clinic after our initial longevity study were dying at much younger ages than previously 
observed.  
Initially, we suspected a virus in the colony but further analysis revealed that only 
the CAM-α1AAR mice were dying sooner. Analysis of the lifespan and F generation data 
showed a significant difference in lifespan in CAM-α1AAR mice starting at the F16 generation 
(Figure 33A, F(13, 69) = 12.49, p < 0.0001), post-hoc comparisons in Table 5). By the F20 
generation, some mice were not surviving past weaning or shortly after due to 
hydrocephaly and thus were not transferred to UND. For comparison, Jackson Laboratories 
refreshes their transgenic lines from cryo-storage after 10 generations to ensure a substrain 
does not  
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Figure 32: Kaplan-Meier survival plots. When the previously published WT mice were excluded from 
analysis there was no significant difference in lifespan between CAM-α1BAR (n = 87) and WT mice (n 
= 58, p = 0.055).  
 
develop due to random mutations, which can become fixed after 6-9 generations (The 
Jackson Laboratory, 2013). 
CAM-α1AAR mice included in the lifespan studies in the 2011 paper and for 
comparison in the 2014 paper were of the F5-F14 generation. CAM-α1BAR animals were 
from the F2-F15 generation but most were in the F5-F8 range. We did not receive any CAM-
α1BAR mice bred past F11. There was a main effect of lifespan vs F generation in CAM-α1BAR 
mice [F(7, 37) = 3.29, p = 0.008], and one post-hoc difference between F6 and F9 (p < 0.05). 
There were no differences between any other generations in CAM-α1BAR mice (Figure 33B). 
For future reference, the lifespan vs F generation data, for which there were no significant 
differences, are also included for the α1AAR-KO [F(7, 42) = 0.59, p = 0.75], α1BAR-KO [F(6, 39) 
= 0.52, p = 0.78], and α1AAR-EGFP [F(3, 18) = 0.85, p = 0.48, Figure 33C, D, and E].
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Figure 33: Age at death vs F generation. A) CAM-α1AAR mice starting at the F16 generation lived 
significantly fewer days than mice of the <F15 generation. B) There was a significant difference in 
lifespan in CAM-α1BAR mice of the F6 and F9 generation but no downward trend was observed. 
There were no significant differences in lifespan between the F generations of C) α1AAR-KO, D) 
α1BAR-KO, or E) α1AAR-EGFP. There was a difference for F) α1BAR-EGFP mice but no post-hoc 
differences. 
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Table 5: CAM-α1AAR vs F generation post-hoc testing results.  
 
Tukey's Multiple Comparison Test Significant? P < 0.05? Summary 95% CI of diff 
4. vs 5. No ns -543.2 to 361.2 
4. vs 8. No ns -610.4 to 343.0 
4. vs 9. No ns -457.2 to 351.8 
4. vs 10. No ns -550.3 to 323.5 
4. vs 11. No ns -583.2 to 321.2 
4. vs 12. No ns -514.2 to 338.5 
4. vs 13. No ns -479.0 to 474.4 
4. vs 15. No ns -385.8 to 400.4 
4. vs 16. No ns -141.4 to 648.1 
4. vs 18. No ns -361.7 to 682.7 
4. vs 19. No ns -214.7 to 622.7 
4. vs 20. Yes *** 203.1 to 1077 
4. vs 22. No ns -2.698 to 950.7 
5. vs 8. No ns -441.5 to 356.2 
5. vs 9. No ns -270.6 to 347.2 
5. vs 10. No ns -372.7 to 327.9 
5. vs 11. No ns -409.2 to 329.2 
5. vs 12. No ns -333.9 to 340.2 
5. vs 13. No ns -310.2 to 487.5 
5. vs 15. No ns -195.5 to 392.2 
5. vs 16. Yes ** 48.30 to 640.4 
5. vs 18. No ns -200.7 to 703.7 
5. vs 19. No ns -32.30 to 622.3 
5. vs 20. Yes *** 380.7 to 1081 
5. vs 22. Yes *** 166.2 to 963.8 
8. vs 9. No ns -262.8 to 424.7 
8. vs 10. No ns -361.1 to 401.6 
8. vs 11. No ns -396.2 to 401.5 
8. vs 12. No ns -323.4 to 415.1 
8. vs 13. No ns -295.0 to 557.7 
8. vs 15. No ns -189.3 to 471.3 
8. vs 16. Yes ** 54.80 to 719.2 
8. vs 18. No ns -182.5 to 770.9 
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Table 5 cont.    
Tukey's Multiple Comparison Test Significant? P < 0.05? Summary 95% CI of diff 
8. vs 19. No ns -22.68 to 698.0 
8. vs 20. Yes *** 392.3 to 1155 
8. vs 22. Yes *** 181.3 to 1034 
9. vs 10. No ns -346.7 to 225.3 
9. vs 11. No ns -387.2 to 230.6 
9. vs 12. No ns -304.8 to 234.5 
9. vs 13. No ns -293.4 to 394.1 
9. vs 15. No ns -153.2 to 273.2 
9. vs 16. Yes *** 89.85 to 522.3 
9. vs 18. No ns -191.3 to 617.7 
9. vs 19. No ns -0.6410 to 514.0 
9. vs 20. Yes *** 406.7 to 978.7 
9. vs 22. Yes *** 182.9 to 870.5 
10. vs 11. No ns -367.9 to 332.7 
10. vs 12. No ns -290.6 to 341.8 
10. vs 13. No ns -270.3 to 492.4 
10. vs 15. No ns -148.9 to 390.4 
10. vs 16. Yes ** 94.70 to 638.8 
10. vs 18. No ns -163.0 to 710.8 
10. vs 19. Yes * 11.63 to 623.2 
10. vs 20. Yes *** 423.1 to 1084 
10. vs 22. Yes *** 206.0 to 968.8 
11. vs 12. No ns -293.9 to 380.2 
11. vs 13. No ns -270.2 to 527.5 
11. vs 15. No ns -155.5 to 432.2 
11. vs 16. Yes ** 88.30 to 680.4 
11. vs 18. No ns -160.7 to 743.7 
11. vs 19. Yes * 7.696 to 662.3 
11. vs 20. Yes *** 420.7 to 1121 
11. vs 22. Yes *** 206.2 to 1004 
12. vs 13. No ns -283.7 to 454.7 
12. vs 15. No ns -157.1 to 347.4 
12. vs 16. Yes ** 86.38 to 596.0 
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Table 5 cont.    
Tukey's Multiple Comparison Test Significant? P < 0.05? Summary 95% CI of diff 
12. vs 18. No ns -178.0 to 674.7 
12. vs 19. Yes * 1.310 to 582.4 
12. vs 20. Yes *** 411.6 to 1044 
12. vs 22. Yes *** 192.6 to 931.1 
13. vs 15. No ns -320.6 to 339.9 
13. vs 16. No ns -76.54 to 587.9 
13. vs 18. No ns -313.9 to 639.5 
13. vs 19. No ns -154.0 to 566.7 
13. vs 20. Yes *** 261.0 to 1024 
13. vs 22. Yes * 49.96 to 902.7 
15. vs 16. Yes ** 51.97 to 440.1 
15. vs 18. No ns -239.9 to 546.3 
15. vs 19. No ns -42.36 to 435.7 
15. vs 20. Yes *** 363.0 to 902.3 
15. vs 22. Yes *** 136.4 to 796.9 
16. vs 18. No ns -487.6 to 301.9 
16. vs 19. No ns -291.1 to 192.4 
16. vs 20. Yes *** 114.6 to 658.7 
16. vs 22. No ns -111.6 to 552.9 
18. vs 19. No ns -375.2 to 462.2 
18. vs 20. Yes * 42.60 to 916.4 
18. vs 22. No ns -163.2 to 790.2 
19. vs 20. Yes *** 130.2 to 741.8 
19. vs 22. No ns -90.35 to 630.3 
20. vs 22. No ns -547.4 to 215.4 
 
There was a main effect for α1BAR-EGFP mice [F(4, 15) = 3.56, p = 0.03], however no post-
hoc differences were found, Figure 33F).  
Around the same time the shortened lifespan of CAM-α1AAR mice was found, a 2 hr 
BrdU stereology pilot study was undertaken using CAM-α1AAR mice of the F22-F23  
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Figure 34: BrdU density in <F10 and F21-22 generation mice. A) CAM-α1AAR mice of a generation 
<F10 had a significantly higher density of BrdU+ cells after a 2 h chase period when compared with 
WT mice (Gupta et al., 2009). B) There was no significant difference in BrdU cell density after 2 h 
between CAM-α1AAR of the F21-22 generation and WT mice. 
 
generation. Surprisingly, in contrast to our previously published findings, no significant 
difference was found in BrdU density in the dentate gyrus after a 2 h chase period [t(14) = 
1.72, p = 0.10, Figure 34, Gupta et al., 2009). While sectioning brains for the stereology 
study hydrocephaly, in particular the lateral ventricles of CAM-α1AAR mice were enlarged in 
comparison with WT mice (Figure 35). Discussions with Robert Papay in Dianne Perez’s lab, 
who performed the sectioning for the 2009 neurogenesis paper, revealed that he had 
previously not noticed any gross differences between WT and CAM-α1AAR brains.  
To help confirm the possibility of a loss of phenotype we decided to use a behavioral test in 
which we had seen robust differences to determine if the behavioral phenotype had also 
changed. At the F12-14 generation, there was a main effect of genotype in time spent 
immobile when comparing WT, CAM-α1AAR, and CAM-α1BAR  mice [F(2, 36) = 29.26, p < 
0.001]. Post-hoc testing showed that CAM-α1AAR mice spent less time immobile (p < 0.001) 
and CAM-α1BAR mice spent more time immobile (p <0.01) when compared with WT mice 
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Figure 35: Lateral ventricle enlargement. The lateral ventricles of A) CAM-α1AAR mice were enlarged 
in comparison to B) WT ventricles.  
 
(Figure 36A, Doze et al., 2009). Additionally, CAM-α1AAR mice spent less time immobile at 
the F15-16 generation when compared with WT [t(50) =3.50, p < 0.001, Figure 36B, Doze et 
al., 2011). When F22-F23 generation CAM-α1AAR mice were tested, there was no significant 
difference in the time spent immobile when compared with WT mice [t(33) = 0.83, p = 0.41, 
Figure 36C]. In an attempt to refresh the CAM-α1AAR line, the Perez lab bred CAM-α1AAR 
mice of F20+ generation to WT mice. Some of the resulting animals were sent to UND and 
the tail suspension test was performed. No significant differences were found between WT 
and CAM-α1AAR mice of this F3 generation [t(25) = 0.78, p = 0.43, Figure 36D]. The next step 
to attempt to regain the phenotype seen previously in CAM-α1AAR transgenic mice would 
be to either refresh the line from cryo-storage, if indeed there is such storage. Otherwise, 
the line must be restarted as it was originally.  
A B 
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Figure 36: Tail suspension test in different F generations. CAM-α1AAR mice spent A) less time 
immobile at the F12-F14 generation (Doze et al., 2009) and B) F15-F16 generation (Doze et al., 
2011). There were no differences in time immobile between CAM-α1AAR mice of the C) F22 
generation or the D) refreshed line at F3.  
 
Cancer Data 
As per the Methods for Pathology, “Animals sacrificed at a younger age were included in the 
analysis to increase statistical power”. During review prior to publication, one reviewer 
requested that additional animals, even if sacrificed at a younger age, be included to make a 
solid conclusion regarding cancer incidence in CAM-α1BAR mice. Initially, the comparison 
between WT and CAM-α1BAR mice for cancer incidence had a p value of 0.07, showing a 
trend toward less cancer in the CAM-α1BAR group. Additional animals, including both mice 
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sacrificed at an earlier age and mice re-evaluated by Dr. Zhou via histology, were included in 
the final published manuscript and in this dissertation.  
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